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ABSTRACT 
 
Socioeconomic factors and the influence of comorbidity in the 
management and survival in lung and prostate cancer 
 
Aim: The presence of co-existing disease is common in cancer patients, and for many cancer 
forms outcomes are associated with socioeconomic status. The present thesis aimed to 
explore possible associations between socioeconomic status and comorbidity on the one 
hand, and clinical management and survival on the other hand, in patients diagnosed with 
lung and prostate cancer. 
 
Methods: In study I, 3,370 patients diagnosed with non-small cell lung cancer between 1996 
and 2004 were identified in the Regional Lung Cancer Register in central Sweden with 
additional information obtained from other population based registers. Study II encompassed 
15,518 patients diagnosed with lung cancer identified in the Thames Cancer Register in South 
East England between 2006 and 2008. A total of 17,899 high risk prostate cancer patients 
(Study III) and all 77,536 men diagnosed with prostate cancer (Study IV) between 1997 and 
2006 were identified in PCBaSE Sweden, a database of prostate cancer patients based on the 
National Prostate Cancer Register of Sweden with additional information retrieved from other 
population based registers. Level of education, a deprivation index, and a socioeconomic index 
based on occupation were used as the main indicators of socioeconomic status. Comorbidity 
burden was assessed using the Charlson comorbidity index. Binary logistic regression and time 
to event analyses were used to address associations between socioeconomic status, 
comorbidity, management and survival. 
 
Results: We observed social differences in time between referral and date of diagnosis and in 
diagnostic intensity in lung cancer patients in Sweden. No social differences in stage at 
diagnosis were observed in Sweden or in South East England. In both regions the most 
privileged lung cancer patients were more likely to receive treatment with curative intent and 
had a better survival, foremost in early stage disease. We observed socioeconomic disparities 
the management of high risk prostate cancer. The likelihood to undergo a bone scan, receive 
curative treatment, and undergo radical prostatectomy was higher in patients with high 
socioeconomic status, a group that experienced a lower mortality. Prostate cancer patients 
with severe comorbidity received curative treatment less often, had a higher all-cause and 
competing cause mortality, but not higher prostate cancer specific mortality. However, in 
analyses given no death from other causes, men with severe comorbidity had a higher 
prostate cancer specific mortality. 
 
Conclusions: Taken together, the results of the present thesis show that socioeconomic 
status influences not only clinical management, but also survival in patients diagnosed with 
lung cancer both in central Sweden and South East England, as well as in Swedish patients 
with high risk prostate cancer. Comorbidity burden influenced both treatment decisions and 
mortality in prostate cancer patients. The pattern of care and survival observed in the most 
privileged groups demonstrates what is achievable and should represent a minimum 
standard for all cancer patients. 
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1 INTRODUCTION 
 
Worldwide, lung cancer is the most common malignancy, and is also the leading cause of 
cancer death globally among men. Among women, lung cancer is the fourth most common 
cancer and the second leading cause of cancer death globally. In Sweden, more than 3,200 
incident lung cancer cases are diagnosed each year. Prostate cancer is the second most 
frequent malignancy in men and the sixth leading cause of cancer death globally. In 2009, 
more than 10,000 men were diagnosed with prostate cancer in Sweden, which makes it the 
most common cancer in men in Sweden. 
 
The Swedish national health care system aims to provide high quality care to all residents on 
equal terms. In an international perspective, cancer care in Sweden is of high quality and 
prospects for survival are better and cancer mortality is lower compared to many other 
countries. However, despite an improved understanding of etiological factors, and progress in 
treatment there is a need to further improve the management of cancer patients. Several 
countries have launched national cancer plans, because of an expected dramatic increase in the 
burden of cancer due to ageing populations. Another concern has been to understand and to 
reduce geographical and social variations in access to cancer care, management and survival. A 
new Swedish national cancer plan was introduced in February 2010.  
 
In recent years, there has been an increased interest in cancer research in the United Kingdom, 
partly because of poor national outcomes compared to other countries, including Sweden. In 
2000, England published a cancer plan that aimed to improve prevention, early diagnosis and 
screening, treatment and survival. There is compelling evidence of socioeconomic disparities 
in cancer survival in England and Sweden, as well as in many other countries. Both the 
Swedish national cancer strategy and the English cancer plan included strategies to reduce 
inequalities in cancer survival. 
 
The origins of observed disparities remain, however, largely unknown. Contributing factors 
are likely to include those related to the tumor, the host and the health care system. In this 
context, it could be hypothesised that tumor characteristics may be influenced by exposures 
associated with socioeconomic standing and that life-style factors influence general health 
status, host defence and their ability to tolerate the treatment. Further, that the knowledge a 
patient has about cancer and its treatment influences health care selection behaviour and 
compliance; and that both overt and subtle processes linked to socioeconomic standing affect 
access to state-of-the-art treatment. 
 
Demographic changes with increased longevity and rapidly aging populations are expected in 
Sweden and in the rest of the world. The number of elderly men and women diagnosed with 
cancer will increase dramatically in a near future. The number of men with cancer in Sweden 
in year 2030 has been estimated to be 130 percent higher than in 2006. Lung cancer will 
continue to increase in women, a change that reflects smoking habits during the late 1960s, 
70s and 80s. Since most patients that are diagnosed with cancer at an older age have several 
comorbidities, it will be increasingly important to consider co-existing disease in the clinical 
management of cancer.  
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The aim of the present thesis was to investigate possible associations between socioeconomic 
status, comorbidity, management and survival in lung and prostate cancer patients identified in 
population based registers in Sweden and South East England. 
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2 BACKGROUND 
 
2.1 Socioeconomic inequalities in health 
 
Social epidemiology is defined as “the branch of epidemiology that address the social 
distribution and social determinants of health” 1, that is, “both specific features of, and 
pathways by which, social conditions affect health” 2. More precisely, the focus of social 
epidemiology is to address the ways in which a person‟s position in the social structure 
influences the likelihood that he or she will develop or survive from the disease 1. The effect of 
social „class‟ (a summary term for various socioeconomic factors, such as occupation, 
education, income, et cetera) in relation to mortality has been addressed since the nineteenth 
century. An English study developed methods for social classification and revealed major 
socioeconomic differences in mortality rates already in the 1860‟s 3. The dramatic decline in 
infectious diseases before the development of modern pharmaceuticals has been attributed to 
changes in social conditions that included nutrition, sanitation and general living conditions 4, 
but also to specific public health interventions, where urban congestion may have played a 
major role 5. 
 
Great Britain has a long tradition regarding of research social inequalities in health. A 
landmark publication was the Black report published in 1980, which concluded that “from 
birth to old age, those at the bottom of the social scale have much poorer health and quality of 
life than those at the top” 6. This conclusion may apply to other countries than Great Britain 
and to a variety of health indicators 7. The Black report denoted Sweden as a country with 
almost no difference in health. However, at that time this conclusion was based on very sparse 
data. 
 
Socioeconomic inequalities in mortality have previously been reported in several populations 8-
14, independent of the socioeconomic indicator used 15. Low socioeconomic status has been 
associated with a higher mortality from cardiovascular disease, diabetes and cancer. 
Converging evidence from studies conducted in Sweden has shown that lower socioeconomic 
status is associated with higher prevalence of health complaints, many chronic conditions and 
adult mortality 16. Findings from Weires et al. showed that higher socioeconomic status was 
associated with a lower overall and cause-specific mortality in Sweden 17. A detailed analysis by 
Shkolnikov et al. demonstrated increasing disparities in absolute mortality in relation to level 
of education in Sweden. Similar patterns have also been observed in Norway and Finland 
between 1971 and 2000 18. The magnitude of social gradients in health is similar in different 
European countries, although the mechanisms underlying these variations may differ. One 
study concluded that the social inequalities in self-rated health were similar in Sweden and 
Great Britain, but the distribution of income across occupational social classes explained a 
larger part of the observed inequalities in Britain than Sweden, which may reflect differences in 
low income and poverty 19. 
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2.2 Socioeconomic inequalities and cancer 
 
Cancer is a term that defines a large group of diseases, all of which involve unregulated cell 
growth. Cancer cells can spread to more distant parts of the body through the lymphatic 
system or blood stream. The risk of developing cancer generally increases with older age 20, but 
cancer can affect people of all ages. Only a few malignancies are more common in children 
than in adults. The prognosis is greatly influenced by the type and location of the cancer and the 
extent of disease at the time of diagnosis. 
 
The importance of studying associations between socioeconomic factors and cancer has been 
discussed in several studies 21. It has been established that there are social class differences in 
incidence and mortality from cancer 22, differences which appear to have increased, in relative 
terms, compared to the nineteenth century 23 24. For most cancer sites, converging evidence 
indicates that the risk is almost twofold when comparing the most disadvantaged group with 
the most advantaged group 25. 
 
The Swedish National Board of Health and Welfare recently reported that the association 
between socioeconomic status and the overall risk of cancer has changed over time for males, 
where men with high socioeconomic status had a higher incidence in the beginning of the 
1990s, while no clear differences were observed in the later calendar periods 26. In women, the 
incidence of all cancer sites was independent of socioeconomic status between 1989 and 2009. 
The overall cancer incidence for men for all cancer sites increased from 969 to 980 per 
100,000 person years between 2007 and 2009. The corresponding incidence for women 
increased from 765 to 768 per 100,000 person years. The incidence of melanoma, prostate 
cancer for men and breast cancer for women was higher for patients with high socioeconomic 
status compared to those with low socioeconomic status, while the incidence of lung and 
cervical cancer shows the reverse trend. This has been observed in several countries 22 27-29, 
including earlier studies based on Swedish data 21 30-32.  The observed differences in the 
incidence may be explained by differences in risk factors such as smoking and ultraviolet 
radiation, as well as prostate specific antigen testing and frequency of mammography screening 
33-36. Since prostate and breast cancer are the two most common cancer sites for men and 
women in Sweden, respectively, this explains why no social differences are observed for all 
cancer sites combined. 
 
A longitudinal study concluded that educational differences in cancer mortality existed among 
men and women in the 1990s, but also that mortality varies by sex, and differs between cancer 
sites across Europe 37. However, the social inequalities in all cancer combined appear to be 
much smaller in Sweden, Norway and Denmark in comparison to other European countries, 
which in part may be explained by differences in the distribution of cancer sites across 
countries. 
 
If studies are restricted to the social class distribution of cancer mortality, results may be 
biased if cancer survival is also linked to socioeconomic position. For instance, in a social 
group with a relatively high probability of survival after diagnosis the event of death will 
tend to be postponed. Consequently, their mortality will appear relatively low even if the 
incidence of the disease is identical with that of a comparison group 21. Thus, to understand 
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the role of socioeconomic differences in early detection and treatment of cancer, it is 
fundamental to also address socioeconomic status in relation to cancer survival 21. 
 
In 1955, Cohart et al. reported an association between socioeconomic status and breast cancer 
survival 38. Results from subsequent research have established that there is a clear social 
pattern in cancer survival 21 39. These social differences tend to occur foremost in cancers that 
have good prognoses, where the stage at diagnosis is a key prognostic factor 21 39. In 1987, 
Vågerö et al. documented social disparities in cancer survival in Sweden using information 
available in the Swedish Cancer Register 40. In that study, the cumulative survival was higher in 
patients with high social class for all cancer sites combined, as well as for specific sites such as 
breast, cervical and rectal cancer, while no social differences in survival were observed for 
lung, stomach and pancreatic cancer. A recent Swedish study concluded that socioeconomic 
differences in patient survival have increased over calendar time for acute myeloid leukemia 
and multiple myeloma 41. During the last two decades there has been an increased interest in 
identifying possible explanations for the observed social differences in cancer survival, which 
has led to more detailed analyses including information on clinical characteristics and 
management. A population based study in Sweden found that social gradients in breast cancer 
survival remained following adjustment for clinical characteristics and treatment factors 42. 
 
Possible explanations for the social differences in cancer survival have been discussed in 
several studies. In 1977 Berg et al. suggested that when there are no differences in treatment, 
socioeconomic variations in survival might be due to differences in when medical help is 
sought, in the general health and life expectancy of the patients, or in the cancer-host 
interaction and the behavior of the cancer 43. In 1987, Vågerö et al. provided a list of 
explanations of inequalities in survival, including roles for factors related to the tumor, the 
patient and the health care system 40. 
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Figure 2.2.1 Possible pathways underlying socioeconomic differences in cancer survival (Source: adapted from 
Franco EL. Epidemiology as a tool to reveal inequalities in Breast Cancer Care 44) 
 
Figure 2.2.1 illustrates possible pathways underlying socioeconomic differences in cancer 
survival. Social differences in stage at diagnosis have been an attractive explanation since it 
represents a key clinical prognostic factor. It has also been suggested that differences in 
histological type of the tumor may explain part of the observed social inequalities 21 39.  
 
Another explanation put forward is that an impaired host resistance among patients with low 
socioeconomic standing would lead to a more rapid tumor growth and spread. Life style 
factors such as physical inactivity, poor nutritional status, obesity, tobacco smoking and 
alcohol consumption are related to low socioeconomic status and may contribute to an 
impaired host resistance. A recent study show that cancer patients with low socioeconomic 
status have a higher prevalence of co-existing diseases which is associated with higher all-cause 
mortality 45.  
 
Since cancer survival is highly dependent on diagnostic procedures and choice of treatment, it 
has been suggested that survival inequalities reflect differences in the clinical management. 
Moreover, the health care provider‟s attitude with regard to management may reflect aspects 
of physician-patient interactions, including a subtle bias towards more action on behalf of 
the physician when treating patients with high socioeconomic status. 
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2.3 Health care systems 
 
2.3.1 An overview of the Swedish health care system and the cancer strategy 
 
Sweden is geographically the third largest country in Western Europe, has a population of 9 
million and is divided into 21 counties and 290 municipalities. There is no hierarchical 
relation between the counties and the municipalities, which all have their own self-governing 
local authorities. Municipalities are responsible for matters relating to their residents and the 
immediate environment. The main task of the county councils is health care, which accounts 
for around 90% of the county councils‟ activities 46. 
 
According to Swedish law, all residents have an equal right to healthcare services 
independent of sex, age, ethnicity, socioeconomic status or residence. The life expectancy in 
Sweden is high; in 2010 it was 83 and 79 years for women and men, respectively 47. With over 
five percent of the population aged 80 years or older, Sweden has the largest proportion of 
elderly in that age bracket in Europe. 
 
While the health care system in Sweden is highly decentralized, national health policy is a 
responsibility that rests with the Government and the Parliament. The Swedish arrangement 
is a national health system, funded through county and municipal taxes, and used by virtually 
all residents augmented by a limited range of care services by private interests. All counties 
and many municipalities contract to varying degrees with private providers, mainly in 
primary care where approximately ten percent of the primary care centers were managed 
privately in 2007. Thus, compared to other countries, the Swedish health care system is 
relatively unified, with county councils and municipalities serving as the primary providers. 
 
In an international comparison, the Swedish health services are of high quality judged on 
accessibility of care, resource and cost levels, range of health care services provided and 
good medical outcomes (e.g. low mortality from cancer). However, compared to other 
countries in the European Union, cancer care in Sweden achieved only a middle ranking 
with regard to the population‟ satisfaction 46. The Swedish national cancer strategy introduced 
in February 2010 48, addresses several key areas of importance to improve cancer care in 
Sweden. There are five overall goals: 
 
 To reduce the risk of developing cancer 
 To improve the quality of cancer management 
 To prolong survival times and improve quality of life after a cancer diagnosis 
 To reduce regional differences in survival time after a cancer diagnosis 
 To reduce differences between population groups in morbidity and survival time. 
 
One key component of the national cancer strategy is to develop six regional nodes, Regional 
Cancer Centers (RCC), in each of the six large health care regions in Sweden 49. The aims for 
the RCCs are: 
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 To formulate and implement a strategy to reduce the risk of developing cancer. 
 To lead and coordinate the cancer care processes within the six health care regions 
 To implement a strategy that assures the provision of psychosocial support to cancer 
patients 
 To strengthen the patient‟s role during the management of the disease 
 To take a leadership role in the medical training and recruitment of a cancer workforce 
 To participate in the implementation of national guide lines, and to use information 
from the national cancer quality registers to ensure high quality cancer care 
 To efficate knowledge transfer between clinical research and cancer care, and to 
increase research collaboration between the councils, universities and the industry 
 To have a clear leadership role with strong support from the councils, and to 
collaborate with the other RCCs 
 To develop a strategic plan to improve the cancer care in the health care region 
 To develop and implement a strategy for “level structuring” of cancer care within the 
health care region. 
 
The six RCCs are expected to collaborate as well as with similar organizational bodies in other 
countries. The RCCs will utilize information from quality registers, health registers and other 
population based registers both for quality control and research. 
 
 
2.3.2 An overview of the National Health Service in England and the cancer plan 
 
The health care system in England is mainly built on the National Health Service (NHS) that 
provides health care to all permanent residents in the United Kingdom. Within this system, 
health care is free at the point of use and paid for from general taxation. The NHS provides 
the majority of health care in England, including primary care, in-patient care, long term health 
care, ophthalmology and dentistry. Since the start of NHS in 1948, private health care has 
developed in parallel. It is paid for largely by private insurance, but is used by less than eight 
per cent of the population and generally as a top-up to NHS services. 
 
In England more than 200,000 people are diagnosed with cancer, and around 120,000 people 
die from the disease annually 50. Several studies show that cancer survival rates are lower in 
England than other countries in Europe 51-54. In July 2000, a national cancer plan was 
introduced with the goal to support prevention and to improve cancer management for all 
patients 55. More specific aims were to save more lives, to ensure the right to professional 
support and care based on the best treatment available, to reduce inequalities in incidence, 
mortality and survival, and to build the future cancer workforce through strong clinical cancer 
research. 
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2.4 Population based records and quality registries in Sweden 
 
Sweden has a long history of population based records. In the 17th century the church gathered 
information with the aim to collect taxes and to identify men eligible for military service 56. In 
1749, a nationwide reporting system for cause of death was introduced,  which was in 1951 
adapted to standards of the international World Health Organization 57. During the 1960‟s 
population records were computerized and in 1967 a check digit was added to an individually 
unique personal identity number that had been introduced in 1947. 
 
Administrated by the National Board of Health and Welfare, the Swedish Cancer Register was 
founded in 1958 58. The recording of incident cancer cases is mandatory by Swedish law with 
the primary aim of monitoring cancer incidence and mortality trends. However, to fill the gap 
left by the lack of primary monitoring variables such as clinical characteristics, mode of 
detection, diagnostic procedures and treatment modalities in the Swedish Cancer Register, 
cancer quality registers have been increasingly used for quality control and research. Currently 
there are 25 national cancer quality registers that contain detailed information on demographic 
factors, clinical characteristics and aspects of management 59. These databases are extensively 
used for local, regional, and national monitoring of cancer care. Research based on quality 
registers is often focused on long-term outcomes and possible causes of differences in cancer 
survival. The quality registers are also used to identify groups of patients that can be studied in 
more detail to improve the understanding of tumor biology. 
 
 
2.5 Survival analysis 
 
Survival analysis from population based studies may have different interpretations for 
different audiences. Survival estimates based on population based studies are in general 
lower than survival rates obtained from clinical trials. For clinicians, the population based 
estimates can be used as an approximate benchmark for cancer patient survival 60. For policy 
makers, an improved survival rate implies that resources need to be allocated to subsequent 
treatment, monitoring, and palliative care for surviving cancer patients 60. For the general 
public, both cancer incidence and survival may appear more relevant than mortality since 
they relate to groups that still are alive 60. There are several factors, such as comorbidity and 
socioeconomic status that might distort the interpretation of survival differences between 
patients from various groups. Other factors of importance include completeness, quality and 
validity of the information available in population based registers.  
 
 
 
2.6 Lung cancer 
 
Lung cancer is a disease characterized by uncontrolled cell growth in tissues of the lung 
(Figure 2.6.1), and most lung cancers are carcinomas that derive from epithelial cells, in the 
bronchial tree.  
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Figure 2.6.1 Anatomy of the lungs (Source: Swedish Cancer Society, illustrated by Roland Klang) 
 
Lung cancer is one of a few cancers for which one main risk factor has been identified. 
Following the first reports in the 1950s, epidemiological studies have demonstrated with 
overwhelming evidence that tobacco smoking causes lung cancer 61. Tobacco smoking is 
estimated to account for 80% of the worldwide lung cancer burden in men and at least 50% 
for women 62 63. Lung cancer is today the most common malignancy in the world, with an 
estimated 1.61 million incident cases in 2008, representing 12.7 % of all cancers diagnosed in 
that year 64. 
 
In 2008, the age standardized incidence rates of lung cancer was generally higher in men 
compared to women (Figure 2.6.2). Among men, the highest incidence rates of lung cancer 
were observed in North America, Europe, Asia and Australia. The highest incidence rates for 
women were found in North and South America, Europe, Australia and China. 
 
 
Figure 2.6.2 Age standardized incidence rates of lung cancer per 100,000 for A) men and B) women in 
2008. Dark colored areas have the highest incidence rates, whereas the areas with the brightest color have the 
lowest incidence (Source: GLOBOCAN 2008) 
 
More than 3,200 people in Sweden and more than 40,000 in England receive a lung cancer 
diagnosis each year 65-67. Between 1980 and 2008, the European age standardized incidence 
of lung cancer rates per 100,000 among men decreased from 113 to 59 in England and from 
39 to 31 in Sweden 66 68. The opposite has been observed for women, where the incidence 
rates during the same calendar period increased from 28 to 39 and from 12 to 26 per 
100,000 in England and Sweden, respectively. The gender-specific incidence rate patterns are 
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likely to be explained by the long time lag between exposure to risk factors for lung cancer, 
primarily smoking and the development of the disease. Smoking patterns in Sweden have 
changed dramatically during the last decades. Between 2004 and 2008, smoking among 
women decreased from 19% to 14%, whereas the proportion of men that smoked on 
regular basis decreased from 14% to 11% 69. 
 
 
 
Figure 2.6.3 Age standardized incidence of lung cancer per 100,000 person years by calendar year, sex and 
socioeconomic status in Sweden (Source: National Board of Health and Welfare) 
 
The incidence of lung cancer in Sweden is higher among residents with low socioeconomic 
status compared to those with middle or high socioeconomic background (Figure 2.6.3), a 
pattern which also is present in many other countries 33 70. The relative gap in lung cancer 
incidence between low and high socioeconomic groups in Sweden has increased over time, 
foremost among women. It has been suggested that Sweden is in the last phase of the 
smoking epidemic, i.e. the prevalence of smoking is declining among both men and women, 
and smoking has primarily become a habit of the lower socioeconomic groups 71. In a cohort 
study based on information from ten European countries, adjustment for smoking explained 
more than 50% of the inequalities in lung cancer risk related to educational level 33. 
 
Fatality ratio is high in lung cancer and in 2008 the ratio of mortality to incidence was 0.86 64. 
In several European countries lung cancer mortality varies between educational groups 72 73, 
and data suggest that differences in smoking contribute to the educational differences in 
overall mortality in most countries 33. 
 
In clinical practice, lung carcinomas have divided into non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC). Approximately 80% of all patients are diagnosed with NSCLC 
that include three major subtypes; adenocarcinomas, squamous cell carcinomas and 
undifferentiated large cell carcinomas. Results from a population based study in South East 
England suggested that adenocarcinoma was less strongly related to low socioeconomic status 
than other subtypes 74, which could reflect differences in smoking history. A Swedish study, 
found a positive association between low socioeconomic status and the risk of squamous cell 
12 
 
carcinoma, and concluded that the association could be mediated by smoking, life-style or 
occupational exposures 75. 
 
The extent of the disease is based on tumor size (T), presence of regional lymph nodes (N) 
and/or distant metastases (M) according to the TNM classification 76, and further classified 
into clinical stages according to Table 2.6.1. 
 
Table 2.6.1 Stage at diagnosis is based on tumor size (T), presence of regional lymph nodes (N) and distant 
metastases (M) 
 
 
 
The literature regarding socioeconomic status and stage at diagnosis is sparse and the results 
are contradictory. A study on non-small cell lung cancer data observed no social differences in 
stage at diagnosis 77, while another population based study found evidence that deprived 
patients with lung cancer were more likely to present with localized disease 78. A recent Danish 
study indicated that patients with low education were more likely to be diagnosed with an 
advanced stage at diagnosis 79. 
 
Often, there are no clear signs and symptoms in the early stages of lung cancer and symptoms 
may not occur for a decade or more after the initiation of the tumor. When symptoms occur, 
they often indicate that the disease has progressed to an advanced stage and may include 
cough growth, chest pain or hemoptysis 80. However, these symptoms, foremost cough, are 
also common in people free of lung cancer. An important warning sign is if symptoms change 
or become worse. It has been suggested that gender, health beliefs, and socioeconomic status 
influence how symptoms are perceived by the individual patient 81.  
 
Because of the absence or lateness of symptoms, the majority of lung cancer patients are 
diagnosed with advanced disease. In 2009, only 24 percent of the patients had early stage 
disease (stage IA-IIB) at time of diagnosis according to the National Lung Cancer Register of 
Sweden 82. 
 
Lung cancer is suspected when an abnormal spot is found on a chest X-ray. If the abnormality 
appears malignant, further diagnostic tests are undertaken. Diagnostic procedures and staging 
methods in lung cancer include chest X-ray, Computerized Tomographic (CT) scan, Magnetic 
resonance imaging (MRI), Positron emission tomography (PET) scan, sputum cytology, 
bronchoscopy, needle biopsy, thoracentesis or mediastinoscopy. Lung cancer most often 
metastasizes to the liver, the adrenal glands, the brain and the bones. To determine the spread 
of the disease, common tests include CT scan of the abdomen, CT scan of the brain and a 
bone scan. 
M0 T1 T2 T3 T4
N0 IA IB IIB IIIB IV
N1 IIB IIB IIIA IIIB IV
N2 IIIA IIIA IIIA IIIB IV
N3 IIIB IIIB IIIB IIIB IV
IV IV IV IV M1
Stage at diagnosis
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Treatment depends on the type of lung cancer, anatomical location, general performance 
status, and the extent of the disease. Surgical resection, radiotherapy and chemotherapy are 
used alone or together 83. Since small-cell lung cancer (SCLC) usually grows and spreads faster 
than non-small cell lung cancer (NSCLC), the treatment for SCLC is different from the 
treatment of NSCLC 83 84. 
 
In early stage (stage IA-IIB at diagnosis) SCLC, the common treatment is chemotherapy and 
radiotherapy of the lung 84. Due to the high risk of dissemination to the brain, it is also 
recommended that patients with early stage SCLC receive radiotherapy to the brain. If there is 
no sign of spread to the lymph nodes in the center of the chest, surgery is the choice of 
treatment, often followed by chemotherapy and sometimes radiotherapy 84. However, if the 
disease already has spread at the time of diagnosis, surgery is not possible. In a more advanced 
SCLC, the common treatment is chemotherapy, but also radiotherapy or biological therapy 84.  
 
In early stage (stage IA-IIB at diagnosis) NSCLC, the common treatment is surgery to remove 
part of the lung (lobectomy) or the whole lung (pneumonectomy) 83. If surgery is not possible 
because of co-existing diseases or general health status, radiotherapy is the choice of treatment. 
Most patients are also likely to receive adjuvant chemotherapy in order to decrease the risk of 
recurrence. In stage III NSCLC, the most common treatment is radiotherapy, often in 
combination with neo-adjuvant and adjuvant chemotherapy. In stage IV NSCLC disease, 
treatment aims to control the cancer for as long as possible and to reduce symptoms. It has 
been shown that chemotherapy prolongs survival time as well as relieves symptoms in this 
stage, but also that radiotherapy and biological therapies can achieve symptom control 83. All 
treatment modalities are associated with a variety of potentially severe and serious side effects. 
 
The prognosis of lung cancer is in generally poor, and lung cancer remains the leading cause of 
cancer-related death despite some advances in treatment. Long-term survival is highly 
dependent on the extent of the disease at time of diagnosis and access to surgical resection. 
At least one study has found evidence that socioeconomic status is associated with low rate of 
surgery 85. 
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Figure 2.6.4 Cumulative overall survival by stage at diagnosis in patients diagnosed with lung cancer between 
2002 and 2009 (Source: The National Lung Cancer Register of Sweden) 
 
Figure 2.6.4 illustrates the cumulative overall survival by stage at diagnosis of lung cancer 
patients diagnosed in Sweden between 2002 and 2009. The five years overall survival in 
patients diagnosed with stage IA and IV at diagnosis were 60% and 3%, respectively. The 
majority of the patients diagnosed with lung cancer succumb to the disease, and not from 
competing causes. Patients with NSCLC have a better prognosis compared to those with 
SCLC. Other factors associated with somewhat better survival include a good general health 
status 86, female sex 87, and being a non-smoker 86. Population based studies show that lung 
cancer survival differs between countries, e.g. with a five-year relative survival of 6.5% and 
11.3% for men and 8.4% and 15.9% in women in England and Sweden, respectively 52. 
 
Results are diverging regarding possible associations between socioeconomic status and 
survival, particularly since most studies to date have lacked information on clinical 
characteristics 88-92.  
 
 
2.7 Prostate cancer 
 
The prostate is a gland situated below the male bladder and in front of the rectum (Figure 
2.7.1). Almost all prostate cancers are adenocarcinomas (99%) derived from the glandular 
epithelial cells.   
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Figure 2.7.1 Male anatomy, 1 bladder, 2 prostate, 3 vas deferens and 4 testicular (Source: Swedish Cancer 
Society, illustrated by Roland Klang) 
 
The incidence of prostate cancer has seen increased dramatically in Europe in recent decades, 
with an estimated 382,000 incident cases diagnosed in 2008 20. In Sweden, the incidence has 
also increased, and more than 10,000 Swedish men were diagnosed with prostate cancer in 
2009 65. Approximately 2,500 men die from prostate cancer each year, which make prostate 
cancer the leading cause of cancer death in Sweden 93.   
. 
 
Figure 2.7.2 Age standardized incidence rates of prostate cancer per 100,000 for men in 2008. Dark 
colored areas have the highest incidence rates, whereas the areas with the brightest color have the lowest incidence 
(Source: GLOBOCAN 2008)  
 
In 2008, the incidence rates of prostate cancer were higher in developed than in developing 
countries (Figure 2.7.2). This pattern and increasing incidence trends in developing countries 
are likely to be explained by the introduction of the prostate specific antigen (PSA) testing 
amongst men with or without symptoms. Increased longevity, better disease awareness and 
generally improved diagnostic techniques over time may also have contributed to the observed 
trends.  
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Figure 2.7.3 Age standardized incidence of prostate cancer per 100,000 person years by calendar year and 
socioeconomic status in Sweden (Source: National Board of Health and Welfare) 
 
Swedish men with high socioeconomic status have a higher incidence of prostate cancer 
compared to males with a middle or low socioeconomic background (Figure 2.7.3). Similar 
patterns have been observed in other countries 94. The socioeconomic gradient in incidence 
has been relatively stable over calendar time in Sweden.  
 
In contrast to many other malignancies, the understanding of the etiology of prostate cancer 
remains limited. Age represents a well-documented risk factor, but area of residence, ethnicity 
95, and family history 96 also appear to play a role, while the relationship between 
environmental and lifestyle factors and risk remains unclear 97. In Sweden, the median age at 
diagnosis decreased from 74 to 69 between 1997 and 2010, which can be attributed to a more 
frequent use of the PSA test 65. There are clear geographical variations in the incidence of 
prostate cancer, where populations in developed countries have the highest risk (Figure 
2.7.2). The observed geographical variations between countries could partly be explained by 
differences in diagnostic intensity, but is also likely to reflect genetic and life-style factors. The 
incidence is higher and the mortality rate is two times higher in African-American compared 
to Caucasian men 98. Results from twin studies suggest that prostate cancer has a strong 
heritable component, with an estimated 30 to 40 percent of the risk being explained by genetic 
factors 99. The risk is higher if a brother and the father has the disease, and the younger the 
brother or the father was at diagnosis, the higher the risk 96. However, recent findings from 
Sweden suggest an increased diagnostic activity among men with a family history of prostate 
cancer may explain their increased risk of prostate cancer 100. The same study also indicated 
that high socioeconomic status among index patients was associated with a significant 
increased risk of diagnosis of prostate cancer among their brothers, especially for T1c tumors 
100. Other factors, including androgens 101 102, diet 103, physical activity 104, sexual activity, 105 
inflammation, 106 and obesity 107 have been suspected to be related to risk, but their role in 
prostate cancer etiology remain unclear. 
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Diagnostic and staging procedures in prostate cancer include digital rectum examination 
(DRE), prostate specific antigen (PSA) testing, trans-rectal ultrasonography (TRUS), skeletal 
scintigraphy, and/or the Gleason score assessed from a tissue specimen. The DRE is an 
examination in which the doctor palpates the prostate to search for abnormalities 108. PSA is a 
glycoprotein produced by the prostate that may be found in an increased amount in the blood 
of men who have prostate cancer, benign prostatic hyperplasia, or infection or inflammation 
of the prostate 109. The DRE and PSA exams can often detect suspicions abnormalities, but 
they cannot always determine whether they are due to cancer or a less serious medical 
condition. However, results from these tests form a basis for the physician to perform a 
biopsy of the gland. TRUS is a less common diagnostic procedure, where a probe is inserted in 
the rectum that sends out sound waves to visualize the prostate and search for abnormal areas 
108. 
 
Since the PSA test was introduced in Sweden in the 1990s, an increasing number of prostate 
cancer are detected in asymptomatic men. There are two ongoing screening trials that are 
evaluating if the PSA test should be introduced on a wider scale, one is the European 
Randomized Study of Screening for Prostate Cancer and the other is the Prostate, Lung, 
Colorectal, and Ovarian cancer screening trial 110 111. After 15 years of follow-up, the European 
trial reported favorable results for the PSA test compared to patients diagnosed because of 
symptoms when the outcome has been overall and prostate cancer mortality 110. However, 
problems with sensitivity and specificity of the test together with too short follow-up time in 
both trials are likely to extend the ongoing debate surrounding the PSA test for many years. 
An English study found that uptake clearly varies by socioeconomic status and concluded that 
PSA testing in general practice  is currently skewed towards older men, and that current policy 
enabling all men to make an informed choice about PSA testing is not being effectively 
implemented 34. The prevalence of urological symptoms in relation to socioeconomic status 
has not been described. However, one study found no association with educational status or 
household income after adjusting for age 112. 
 
The introduction of the PSA test has increased the proportion of prostate cancer patients 
diagnosed with localized disease and, bone metastases found in screening trials have been 
shown to be detected at diagnosis in less than ten percent of patients. Early detection of bone 
metastases is critical in the management of men diagnosed with high risk prostate cancer. 
Skeletal scintigraphy (also referred as bone scan) has been considered the most reliable method 
for early detection and monitoring of bone metastases in men with prostate cancer 113. 
 
The extent of the disease is based on tumor size (T), presence of regional lymph nodes (N) 
and/or distant metastases (M) according to the TNM classification 108, but also by Gleason 
score (the pathological grading) and the level of prostate specific antigen (PSA) (Table 2.7.1).  
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Table 2.7.1 Clinical risk groups based on tumor size (T), presence of regional lymph nodes (N) and distant 
metastases (M), Gleason score and level of prostate specific antigen (PSA) 
 
Treatment decisions are based on the extent of the disease, serum level of PSA, tumor size 
and Gleason score, but also by the condition of the host based on age, comorbidities, 
remaining life expectancy, and symptoms such as sexual function and anxiety. Based on these 
considerations, treatment pathways for prostate cancer are complex and differ greatly between 
doctors, hospitals, regions and countries. Treatment modalities include radical prostatectomy, 
radiotherapy, watchful waiting (with delayed entry of palliative care) or active surveillance (with 
delayed entry of curative care) and sometimes endocrine therapy 108. Radical prostatectomy has 
been evaluated in both observational and randomized controlled trials, and recent trial data 
comparing radical prostatectomy with watchful waiting has favored radical prostatectomy in 
light of a significant reduction in mortality 114 115. Results from several studies indicate that men 
with high socioeconomic status are more likely to receive a curative treatment 116 117. In 
palliative care, numerous forms of endocrine therapies (including castration) are used alone or 
in combinations, but also radiotherapy and chemotherapy are used to target skeletal metastases 
108. 
 
The prognosis of prostate cancer varies greatly between countries, where a recently published 
population based study reported a five-year relative survival of 76.4% and 83.0% in England 
and Sweden, respectively 51. Within countries survival has increased during the last decades, 
which may reflect a lead time bias following a more widespread use of PSA testing.     
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Figure 2.7.4 Cumulative prostate cancer specific survival by clinical risk groups in men diagnosed with 
prostate cancer between 1997 and 2009 (Source: the National Prostate Cancer Register of Sweden) 
 
Figure 2.7.4 illustrates prostate cancer specific survival by clinical risk groups of men 
diagnosed with prostate cancer in Sweden between 1997 and 2009. The five year survival in 
patients with low risk and distant metastases were 99% and 38%, respectively. Social 
differences in survival of prostate cancer have been addressed in several studies in most of 
these, survival was poorer in low socioeconomic groups 118-121. 
 
 
2.8 Co-existing disease among cancer patients 
 
Older age is an important risk factor for cancer. The risk of developing cancer has been 
estimated to 1/10,000 per year in an individual aged 20 years, compared to 1/100 at age 80 
years 122. The presence of other medical conditions increases with age and it has been shown 
that cancer patients aged 70 and older have on average three comorbidities 123. These co-
existing diseases can affect the choices of management and prognosis.  
 
Due to increased longevity and rapidly aging populations in Sweden and many other 
countries, the number of elderly men and women will continue to increase. A recent study 
has indicated that if current life expectancy trends continue, more than half of the babies 
born in wealthy nations today will live to be 100 years 124. Since comorbidity burden 
increases with age, it will be increasingly important to consider co-existing disease in the 
clinical management of cancer patients. In many parts of the world the incidence and 
mortality of cancer is expected to have doubled by 2020 125. Patients with concomitant 
diseases may not receive optimal treatment due to preconceived notions about life 
expectancy and ability to tolerate therapy and side effects. There is epidemiological evidence 
that cancer patients with severe comorbidity receive less aggressive treatment, and that the 
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presence of concomitant disease affects overall and competing cause survival 123 126-128. Some 
researchers have addressed comorbidity in relation to cause-specific survival with diverging 
results 122. 
 
The comorbidity burden in cancer patients tends to vary by tumor sites. Approximately 85% 
of lung cancer patients diagnosed in Sweden are current or former smokers. Since smoking 
is also associated with many other medical conditions, lung cancer populations tend to have 
a higher comorbidity burden compared to patients with other cancer forms or to the 
background population. In contrast, patients diagnosed with prostate cancer, particularly 
those with low risk tumors, tend to be healthier than the background population in the same 
age. 
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3 AIMS 
 
The opportunities available in Sweden for individual record-linkages between different 
population based registers offer unique possibilities both for epidemiological research and to 
examine in detail aspects of management in cancer care. The overarching aim of the present 
thesis was to investigate possible associations between socioeconomic status, comorbidity, 
management and survival in patients diagnosed with lung and prostate cancer identified in 
population based registers in South East England and Sweden.  
 
 
 
Specific aims: 
 
o Study I: to assess possible associations between socioeconomic status, management 
and survival in patients diagnosed with non-small cell lung cancer in central Sweden 
between 1996 and 2004.  
 
 
o Study II: to examine possible social gradients in lung cancer survival and assess if any 
such variation can be attributed to social differences in comorbidity, stage at diagnosis 
and treatment for a setting of patients diagnosed with lung cancer in South East 
England between 2006 and 2008. 
 
 
o Study III: to study aspects of management and mortality in relation to socioeconomic 
status in patients diagnosed with high risk prostate cancer in Sweden between 1997 
and 2006. 
 
 
o Study IV: to explore the influence of comorbidity on treatment decisions and 
mortality in patients diagnosed with prostate cancer in Sweden between 1997 and 
2006.  
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4 MATERIAL 
 
4.1 Data sources 
 
The studies in this thesis were conducted using a population based cohort design. The 
Swedish studies were based on information in population based quality registers with 
additional data obtained by means of record-linkage to other population based health registers 
using the individually unique National Registration Number, assigned to all residents at time of 
birth or first residency. The English lung cancer study was based on information from a cancer 
register in South East England with additional information retrieved from hospital episodes 
statistics and a lung cancer audit database. The following registers were used in the present 
thesis: 
 
 
4.1.1 The Swedish Cancer Register 
 
Administrated by the National Board of Health and Welfare, the Swedish Cancer Register 
(SCR) was established in 1958 and covers the total population 58. Reporting of all newly 
diagnosed tumors to the SCR is regulated by law and is mandatory for clinicians, pathologists 
and cytologists. The SCR includes information on selected demographic characteristics, tumor 
site, date of diagnosis, histological type, and stage at diagnosis (collected since 2004). Close to 
99% of all cases are reported, and for 95% of the cases, the register receives two notifications. 
For all calendar years, the SCR translates newly reported cases back to the International 
Classification of Diseases-7 (ICD-7).    
 
 
4.1.2 The Regional Lung Cancer Register in central Sweden 
 
The population based Regional Lung Cancer Register (RLCR) in central Sweden (Uppsala-
Örebro health care region) was established in 1995 to monitor quality of care after the 
introduction of regional management guidelines for lung cancer 129. The RLCR covers >98% 
of all patients diagnosed with lung cancer in central Sweden, an area with a source 
population of 1.9 million. The RLCR contains detailed information on sex, age at diagnosis, 
waiting time, smoking status (current, former and non-smoker), performance status 
(according to the WHO classification), mode of detection, diagnostic procedures, 
histopathology, stage at diagnosis (according to the TNM classification) and planned initial 
treatment (surgery, chemotherapy, radiotherapy and no active curative treatment).  
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4.1.3 The Thames Cancer Register 
 
The Thames Cancer Register is a population based cancer register (one of eleven cancer 
registries in the United Kingdom) and currently covers a source population of 12 million 
people in South East England (London, Kent, Surrey and Sussex) 130. In total more than 2.7 
million cancer cases are recorded with registration based on clinical and pathological 
information received from hospitals and from death certificates provided by the Office for 
National Statistics. The follow-up of deaths of registered cancer patients is passive, which 
means that all deaths (including cancer and non-cancer deaths) are notified to the Register, 
cancer deaths by the Office of Population Censuses and Surveys, and deaths due to other 
causes than cancer by the National Health Service Central Register. 
 
 
4.1.4 The National Prostate Cancer Register of Sweden 
 
A regional prostate cancer register was established in one of the six Swedish health care 
regions (South East) in 1987 131. In 1995, a urology expert group decided to develop a 
national clinical database for the management of prostate cancer, the National Prostate 
Cancer Register (NPCR) of Sweden 132 133. Since 1998 the NPCR covers all health care 
regions in Sweden. The database includes patients diagnosed with prostatic adenocarcinoma 
while cases detected at autopsy are not included. The NPCR is constantly updated against 
the Swedish Cancer Register. Currently the NPCR covers more than 98% of all patients 
diagnosed with prostate cancer who were registered in the Swedish Cancer Register. 
Through December 31, 2006, the NPCR contained data on more than 75,000 cases with 
detailed information on mode of detection, TNM stage, Gleason score, serum levels of 
prostate specific antigen (PSA) and primary treatment within six months of date of 
diagnosis. 
 
The prostate cancer database Sweden (PCBaSe) is a unique database with over 75,000 
incident cases with a record prostate cancer identified in the NPCR with additional data on 
inpatient and outpatient care, patterns of prescribed drug use and socioeconomic and familial 
factors obtained by means of record-linkage to other data sources 134.  
 
Figure 4.1.4.1 PCBaSe Sweden; prostate cancer patients identified in the NPCR of Sweden with additional 
information retrieved from other population based registers in Sweden 
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Figure 4.1.4.1 illustrates PCBaSe Sweden, with record-linkages between NPCR of Sweden 
and other population based registers in Sweden. Several topics in prostate cancer clinical 
epidemiology have been addressed using this database. To date, 11 studies have been 
published based on data from PCBaSe Sweden.  
 
 
4.1.5 The National Patient Register 
 
From 1987 the National Patient Register, administrated by the National Board of Health and 
Welfare, includes information on hospital admissions and discharges from all public hospitals 
in Sweden 135. Each inpatient discharge record contains dates of hospital admissions and up to 
eight discharge diagnoses, coded according to the International Classification of Diseases.  
 
 
4.1.6 The Swedish Cause of Death Register 
 
Information on cause of death was obtained from the Cause of Death Register, administered 
by the National Board of Health and Welfare. The database was established in 1952 and 
includes records of causes of death reported by the attending physician according to WHO 
International Classification of Diseases. The number of non-reported deaths was estimated 
at 0.7% in 2006 93. 
 
 
4.1.7 Longitudinal integration database for health insurance and the labor market  
The longitudinal integration database for health insurance and labor market studies (LISA) is 
managed by Statistics Sweden and integrates regularly updated information from the labor 
market, and educational and social sectors 136. Individual level data has been collected since 
1990 for all residents in Sweden aged 16 and older, and connections to family and places of 
employment are also available. The LISA database includes Census data, information on 
country of birth, year of immigration, disposable income, level of education, socioeconomic 
index, receipt of welfare benefits and employment status. 
 
4.2 Study populations 
 
Study I was based on data retrieved from the Regional Lung Cancer Register in central 
Sweden, with additional information obtained by means of record-linkages to the Cause of 
Death Register and the LISA database.  
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Figure 4.2.1 Flow chart of lung cancer cohort assembly based on information in the Regional Lung Cancer 
Register between 1996 and 2004, and other data sources 
 
For the purpose of Study I, we included patients with a record of lung cancer (162 in ICD-9) 
diagnosed between 1996 and 2004. Lung cancers not recorded as the primary tumor and those 
diagnosed at autopsy or before age 30 or with negative survival time were excluded, and 
immigrants and patients with forms of lung cancer other than non-small cell lung cancer were 
also excluded (Figure 4.2.1). The final study population consisted of 3,370 incident cases of 
non-small cell lung cancer.  
 
In study II, lung cancer cases were extracted from the Thames Cancer Register in South East 
England, with additional information obtained from hospital episode statistics and the 
National lung cancer audit database. A total of 16,183 patients were diagnosed of lung cancer 
between 2006 and 2008.  
 
 
Figure 4.2.2 Flow chart of lung cancer cohort assembly based on information in the Thames Cancer Register 
between 2006 and 2008 
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After excluding death-certificate-only cancer registrations (601 cases or 3.7% of the total), the 
final study population included 15,582 lung cancer cases (Figure 4.2.2).  
 
Study III and IV were based on PCBaSe Sweden, with prostate cancer cases identified in the 
National Prostate Cancer Register of Sweden between 1997 and 2006. 
 
Figure 4.2.3 Flow chart of prostate cancer cohort assembly based on information in the National Prostate 
Cancer Register of Sweden between 1997 and 2006, and other data sources 
 
In study III, the final study population was restricted to 17,522 patients diagnosed with high 
risk prostate cancer according the flow chart presented in Figure 4.2.4. In study IV, the final 
study population was based on all prostate cancer cases registered in between 1997 and 2006 
(n=77,536). 
 
 
4.3 Indicators of socioeconomic status 
 
In the present thesis several different indicators of socioeconomic standing were included. In 
the first study, level of education was used as the main indicator for socioeconomic status, but 
associations in relation to socioeconomic index, household disposable income and number of 
persons in the household were also assessed. Study II utilized a deprivation index based on 
postcode of residence, while in study III a socioeconomic index based on occupation was 
used. 
 
Educational attainment was classified into three groups according to total numbers of years 
of schooling: low ≤ 9 years, middle 10-12 years and high ≥ 13 years, which in the Swedish 
school system corresponds to mandatory school, high school or post high school education 
(college and university). 
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Socioeconomic index (SEI) was based on occupational codes from Population and Housing 
Census 1960, 1970, 1980, 1985 or 1990. In study I, the SEI was categorized into three levels, 
low (blue-collar and low level white-collar), high (intermediate and high level white-collar 
workers and the self-employed) and unknown (due to no employment or missing).  In study 
III, socioeconomic index was aggregated into five levels; blue-collar workers, farmers, self-
employed, lower white-collar workers and higher white-collar workers. In both the studies 
where patients were diagnosed after retirement, historical data were used to assess the highest 
lifetime SEI. 
 
Household disposable income was divided into the lowest 50% and highest 50% income. 
 
Number of persons in the household was categorized into one or more persons in the 
household. 
 
A deprivation index was based on the income domain of the 2007 Indices of Deprivation 
released by the Department of Communities and Local Government 137. The income domain 
is mainly influenced by different forms of social income support, in which patients are 
classified based on their postcode of residence and categorized into quintiles of socioeconomic 
deprivation, from the most affluent group to the most deprived group. 
 
 
4.4 The Charlson comorbidity index 
 
The Charlson comorbidity index (CCI) was originally proposed in 1987 by ME Charlson, to 
develop a simple method for classifying co-existing diseases which could predict one-year 
mortality using information on comorbidity from hospital chart review 138. In that study, the 
derivation cohort consisted of 604 patients admitted to a New York teaching hospital during 
one month in 1984. The validation cohort included 685 patients diagnosed with breast cancer 
at a Connecticut hospital from 1962 to 1969. The final Charlson comorbidity index was the 
sum of 19 predefined comorbidities that were assigned weights of 1, 2, 3 or 6. These weights 
were based on the magnitude of the adjusted relative risks associated with each clinical 
condition in a Cox proportional hazards regression model (Table 4.4.1).  
 
Table 4.4.1 Clinical conditions included in the Charlson comorbidity index (Source: Charlson ME, 1987)
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In study II, a modified version of the Charlson comorbidity index was used with the approach 
that all weights except cancer were included to assess the burden of concomitant disease for 
each patient, following retrieval of information on comorbidity from the hospital episode 
statistics in a three-year period preceding the lung cancer diagnosis. In a subsequent step, the 
weights were summed to obtain an overall score, resulting in three comorbidity levels; no (0), 
mild (1), and severe comorbidity (2+). A total of 1,808 (11.6%) lung cancer patients had no 
information available on comorbidity since no link to the hospital episode statistics could be 
established. 
 
In study III and IV, information on medical conditions other than cancer was obtained from 
the Swedish National Patient Register, where the main diagnosis and up to seven secondary 
discharge diagnoses from in-hospital stays preceding the prostate cancer diagnosis were 
retrieved. Malignancies other than prostate cancer were identified in the Swedish Cancer 
Register. All information on concomitant disease was retrieved from ten years before, up 
until the date of the prostate cancer diagnosis. The CCI was then used to assess the burden 
of concomitant disease for each patient with prostate cancer. All 19 weights in Table 4.4.1 
were summed to obtain an overall score for all patients, and that resulted in the three 
comorbidity levels of CCI 0 for no comorbidity, CCI 1 for mild and CCI 2+ for severe 
comorbidity. 
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5 STATISTICAL METHODS 
 
In all four studies, descriptive statistics were calculated using conventional methods. An 
overview of the statistical methods used is presented in Table 5.1. All p-values were two-
sided and statistical significance was considered at p<0.05. Data management was carried out 
using SAS 9.1/9.2, while statistical analyses and graphical illustrations were performed using R 
9.2 and/or STATA 11. 
 
Table 5.1 An overview of the statistical methods used 
 
 
5.1 Binary logistic regression 
 
Binary logistic regression is used in epidemiological research to predict the probability of 
occurrence of an event (treatment or no treatment) by fitting data as a function of one or 
several dependent variables, allowing for management of potential confounders. An odds ratio 
is a natural description of an effect in a probability model and in the studies included, 
estimated odds ratios with 95% confidence intervals are used as a measure of effect. Events of 
interest were stage at diagnosis (study II) and different treatment modalities (all studies) and 
the exposure variables were socioeconomic status and comorbidity burden both univariate and 
adjusted for potential confounders. The goodness of fit of the models was evaluated by using 
the model deviance and likelihood ratio tests were used to assess the relative importance of the 
model covariates.   
 
 
5.2 Time to event analysis 
 
In time to event analysis there are three key parts that should be considered: events, failure 
time and censoring time. The event is defined as the outcome of interest, e.g. lung cancer 
death or prostate cancer death. The date of the occurrence of the event must also be known. 
The time from the baseline (in the present studies, date of cancer diagnosis) to the occurrence 
of the event (the failure) is referred to as the failure time. When an event is not observed 
before end of follow-up, the failure time is referred as right censored (e.g. the patient 
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emigrated during follow-up or is lost from the study for some other reason before the event of 
interest is observed) and the follow-up is defined as censoring time (instead of failure time). In 
the present studies, survival time was defined as the interval between the date of the primary 
diagnosis of lung or prostate cancer and either the date of the event (death due to all causes, 
lung cancer, prostate cancer, and causes other than prostate cancer) or emigration or end of 
follow-up. In study I and II, end of follow-up was on 31 December 2006 and on 31 
December 2009, respectively. In Study III and IV, end of follow-up was on 31 December 
2007. 
 
 
5.2.1 The Kaplan-Meier estimator 
 
The Kaplan-Meier approach 139, also known as the product limit estimator, was used to 
measure the fraction of patients living for a certain time post cancer diagnosis for each variable 
of interest. The Kaplan-Meier estimation leads to a life table with the smallest possible 
intervals which use the maximum amount of information in the data. Although the probability 
calculated at any given interval is not very accurate because of the small number of events, the 
overall probability of surviving to each point (e.g. three-year survival) is more accurate. The 
Kaplan-Meier approach was used to evaluate the cumulative survival (cause-specific and 
overall) comparisons between socioeconomic groups and also in relation to comorbidity 
burden. 
 
 
5.2.2 Cox Proportional Hazard regression 
 
The Cox proportional hazard regression is widely used in time to event analysis 140. The Cox 
model is a semi-parametric model where the baseline hazard function does not have to be 
specified, but where parametric assumptions about the effects of covariates of the hazard 
function do have to be made. Thus, we assume that any two or more hazard rates predicted by 
the model are proportional over time. The Cox model was used in all studies, where relative 
risks were expressed as hazard ratios with 95% confidence intervals. This measure how much 
a covariate increases or decreases the rate of the event of interest, assuming that it acts 
multiplicatively. In the lung cancer studies, both cause-specific and overall deaths were 
considered as an event, with educational level and deprivation index as exposure variables. 
These models were adjusted for demographic, clinical and treatment factors. In the prostate 
cancer studies, overall death was used as an event using the Cox model. The exposure 
variables were comorbidity burden and socioeconomic status adjusted for demographic and 
clinical characteristics. In all models, the Schoenfeld‟s residuals were plotted against survival 
time and tested to verify that assumptions of proportional hazards were fulfilled. 
 
In study II we calculated the relative contribution (%) of adding each covariate separately in 
explaining the possible social variation in mortality between the most deprived (SESQ5) and the 
most affluent (SESQ1) patients as follows:  
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)      
 
Where Model A is the basic model (socioeconomic quintiles and adjusted for sex) and in 
Model B, each covariate is added to Model A. 
 
 
5.2.3 Competing risks 
 
In the Kaplan-Meier approach, and in the Cox model we considered situations where each 
patient could only have one event (all other events were censored). However, there are 
situations where it may not be appropriate to apply the usual survival methods to the time to 
event analysis 141. One such situation is where competing risks are present 142. A competing risk 
arises when a patient can experience more than one type of event and the occurrence of one 
type of event hinders the occurrence of other types of events, e.g. men diagnosed with 
prostate cancer may die of other causes than prostate cancer. This is a competing risk situation 
because death from other causes prohibits the occurrence of prostate cancer death. Prostate 
cancer death is considered the event of interest, while death from other causes is considered a 
competing risk. The group of patients that died from other causes cannot be considered 
censored, since their observations are not incomplete. Since most lung cancer patients 
succumb to their disease, competing risks analysis was only considered in the prostate cancer 
studies (Study III and IV). 
 
 
5.2.4 Cumulative incidence function 
 
Given that the Kaplan-Meier estimator ignores events of all types other the one of interest, it 
can be interpreted as the probability of an event beyond a specific time given that all other 
risks are removed. However, this may be a nonsensical interpretation in many medical 
situations, e.g. if the event of interest is relapse of prostate cancer in the presence of the 
competing risk of death due to non-relapse-related causes, then one would be forced to 
consider the unrealistic case where death due to all non-relapse-related causes was eliminated. 
To estimate the probability of an event in a competing risk situation, Kalbfleisch and Prentice 
suggested the cumulative incidence function 143. The definition of cumulative incidence 
function states that the cumulative incidence is a function of the hazards of all the competing 
events and not solely of the hazard of the event to which it refers. The sum of the cumulative 
incidence function has the nice feature that it equals the complement of the overall Kaplan-
Meier estimate of survival considering failures of any kind. In the third and fourth study, the 
cumulative incidence function was used to estimate the cumulative incidence of death due to 
prostate cancer when death due to other causes also was considered. The cumulative 
incidence functions were stratified on comorbidity and socioeconomic status and expressed 
as the cumulative probability of mortality since diagnosis.  
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5.2.5 Fine and Gray’s Competing risk regression 
 
When competing events are present, the focus will be on the cumulative incidence function 
rather than the survival function. Modeling in the presence of competing risk can be applied 
using the Cox model with competing risks, but either the interpretations have to be 
modified or a lot of work has to be done to assess covariate effects. In 1999, Fine and Gray 
suggested competing risks regression as a useful alternative 144. The Fine and Gray‟s 
competing risk regression was used in the prostate cancer studies, with both deaths due to 
prostate cancer and to other causes as the primary events of interest, where the estimates 
were expressed as subdistribution hazard ratios with 95% confidence intervals. 
 
 
5.2.6 Conditional probability function 
 
Previous studies have indicated that the cumulative incidence function for the event of interest 
may not include a complete understanding of competing risks data. The reason behind this 
indication is that the cumulative incidence function for the event of interest may appear low 
only because the cumulative incidence function for the competing risk is large. Calculating the 
conditional probability is one way to incorporate the two types of information; the event of 
interest and the competing risk 145. The conditional probability is calculated as the probability 
of observing an event of interest, conditional on the patient not experiencing a competing risk 
event. In study IV, we calculated conditional probabilities by comorbidity burden since most 
of prostate cancer patients with severe comorbidity do not die from their disease, and that 
death rate from competing causes increased with comorbidity burden, expressed as the 
conditional prostate cancer mortality since diagnosis. 
 
 
5.2.7 Flexible parametric models 
 
In study II, we estimated the cumulative survival and mortality rates, calculated as number of 
deaths divided by person-years at risk. These estimates were modeled through flexible 
parametric survival models using a restricted cubic spline for the baseline mortality rate. These 
models, similar to the Cox models, provide hazard ratios with 95% confidence intervals as a 
measure of association between exposures and outcome. By modeling the underlying rate 
parametrically, it is possible to estimate various fitted curves from the model, such as the 
cumulative survival. In the Cox models, we estimated a constant hazard ratio between the 
exposure variable throughout follow-up. In the flexible parametric survival framework, the 
hazard ratio for the exposure variable of interest was estimated as a function of follow-up 
using a second spline function. The hazard ratio is then time-dependent due to the underlying 
timescale of time since diagnosis of lung cancer. All flexible parametric survival models were 
estimated using the stpm2-package 146.  
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5.3 Multiple imputation 
 
In study II, we used multiple imputation which is a simulation based approach for analyzing 
incomplete data. Multiple imputation replaces missing values with multiple sets of simulated 
values to complete the data, applies standard analyses to each completed dataset, and adjusts 
the obtained parameter estimates for missing data uncertainty. Multiple imputation handles 
missing data in such a way that a valid statistical inference can be obtained. Since more than 
ten percent of the patients in study II had no information on comorbidity burden, the 
multiple imputation method was applied with information based on their sex, histology and 
treatment factors using chained equations with 60 imputated datasets 147.  
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6 SUMMARY OF STUDIES 
 
6.1 Study I: Social inequalities in non-small cell lung cancer management and 
survival - A population based study in central Sweden 
 
Introduction 
The prognosis of lung cancer is generally poor, with long-term survival depending on early 
diagnosis and surgical resection. Several investigators have shown that men and women with 
low socioeconomic status have an increased risk of developing lung cancer, but few studies 
have examined possible socioeconomic inequalities in access to treatment and in survival. 
The aim of the present study was to examine possible associations between socioeconomic 
status, management and survival in patients diagnosed with non-small cell lung cancer 
(NSCLC). 
 
Material and Methods 
In this population based cohort study, 3,370 patients diagnosed with NSCLC between 1996 
and 2004 were identified in the Regional Lung Cancer Register in central Sweden, with 
record-linkages to the Cause of Death Register and a social database (LISA). While several 
indicators of socioeconomic standing were used, level of education was chosen as the main 
indicator for socioeconomic status, and was categorized in three levels: low, middle and high 
education. Binary logistic regression with odds ratios (OR) and 95% confidence intervals 
(CI) were calculated to assess associations between educational level and care management, 
while Kaplan-Meier estimates and the Cox regression model were used with hazard ratios 
(HRs) to examine associations between educational level and survival. 
 
Results 
NSCLC patients with low education were older at diagnosis, were more often smokers, and 
had a lower performance status compared to patients with high education. There were no 
clear differences by level of education with regard to stage at diagnosis. However, a greater 
diagnostic intensity was observed in patients with high education. A difference in time from 
referral to diagnosis by level of education was observed, foremost in early stage disease, 
where the median waiting time for the low and high education groups was 32 and 17 days, 
respectively.  
 
In early stage disease, following adjustment for demographic and clinical characteristics, the 
likelihood to undergo surgery was higher in patients with high education (OR 2.84; 95% CI 
1.40 to 5.79). Differences in receiving radiotherapy or chemotherapy were most pronounced 
in stage III disease at diagnosis, where 33.8% and 40.6% of patients in the low education 
group compared to 42.5% and 60.5% in the high educational group received radiotherapy or 
chemotherapy, respectively.  
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Figure 6.1.1 Cause specific cumulative survival by stage at diagnosis and level of education 
 
A social difference was observed in survival for all socioeconomic indicators, except for the 
indicator number of people in the household. The social variation in survival was most 
pronounced in early stage disease, where the three-year survival in low and high education 
patients was 39% and 65%, respectively (Figure 6.1.1). In a model adjusted for 
demographic and clinical characteristics, the risk of death was lower among patients with 
high compared to low education, but only in early stage disease (HR 0.58; CI 95% 0.40 to 
0.85). In a multivariate model, when also including treatment, a lower risk of death was 
observed among high educational patients, but only among women in early stage disease 
(HR 0.33; CI 95% 0.14 to 0.77).  
 
Conclusion 
The present results indicate that disadvantaged patients receive less intensive care for non-
small cell lung cancer within the setting of the Swedish National health care system. Of 
particular concern was our finding of disparities in the likelihood to undergo surgery in early 
stage disease, a treatment of significant potential benefit. The pattern of care and survival 
observed in the most privileged groups should represent a minimum standard for all patients 
with lung cancer. 
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6.2 Study II: Social differences in lung cancer management and survival in South 
East England – The role of patient, clinical and treatment factors 
 
Introduction 
Recent studies in the United Kingdom have found evidence of both regional variations in 
treatment intensity and socioeconomic differences in lung cancer survival. The aim of the 
present study was to examine possible social variations in lung cancer survival and assess if any 
such gradients can be attributed to social differences in comorbidity, stage at diagnosis or 
choice of treatment. 
 
Material and Methods 
In this population based cohort study, 15,582 patients in the Thames Cancer Register in 
South East England were diagnosed with lung cancer between 2006 and 2008. 
Socioeconomic status was based on the income domain of the 2007 Indices of Deprivation 
(socioeconomic quintiles). Logistic regression with odds ratios was used to assess 
associations between socioeconomic quintiles, stage at diagnosis and choice of treatment. 
Flexible parametric models and Cox regression with hazard ratios were used to assess 
associations between socioeconomic quintiles and overall survival. 
 
Results 
The likelihood of being diagnosed with early stage disease did not vary by socioeconomic 
quintiles (p=0.58). In early stage NSCLC, and following adjustment for sex, age and 
comorbidity, the likelihood to undergo surgical resection was lowest in the most deprived 
group, but there was no clear trend through all socioeconomic quintiles (p=0.29). In stage III 
disease, there were no socioeconomic differences in the likelihood to receive radiotherapy, 
while in advanced disease or SCLC, receipt of chemotherapy differed over socioeconomic 
quintiles (p<0.01).  
 
 
Figure 6.2.1 Estimated mortality rates by socioeconomic quintiles and time-dependent hazard ratios 
between the most deprived versus the most affluent patients within 12 months of diagnosis by tumor 
subgroups 
 
37 
 
 
In early stage disease and following adjustment for confounders, the hazard ratio between the 
most deprived and the most affluent group was 1.24 (95% CI 0.98 to 1.56). Corresponding 
estimates in stage III and advanced disease or small cell lung cancer were 1.16 (95% CI 1.01 to 
1.34) and 1.12 (95% CI 1.05 to 1.20), respectively.  
 
Figure 6.2.1 illustrates the estimated mortality rates by socioeconomic quintiles and crude 
time-dependent hazard ratios between the most deprived versus the most affluent patients 
within 12 months of diagnosis by tumor subgroups. In early stage disease, the hazard ratio 
between the most deprived and the most affluent group was approximately 1.4 and constant 
through follow-up, while in patients with advanced disease or small cell lung cancer no 
difference was detectable after three months. 
 
Conclusion 
We observed social variations in management, but also in survival in patients diagnosed with 
lung cancer in South East England between 2006 and 2008. These inequalities could not be 
fully explained by social differences in stage at diagnosis, comorbidity and treatment. The 
survival observed in the most affluent patients should set the goal for what is achievable for all 
lung cancer patients managed within the same health care system. 
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6.3 Study III: Differences according to socioeconomic status in the management 
and mortality in men with high risk prostate cancer 
 
Introduction 
In recent studies, we have found evidence of social inequalities in the management and 
survival of patients diagnosed with lung, colorectal and breast cancer in Sweden. Over the 
past two decades, the incidence of prostate cancer has increased rapidly in most Western 
countries with reports of a higher incidence in high compared to low socioeconomic groups. 
The present study aimed to investigate possible associations between socioeconomic status, 
metastatic work-up, treatment and mortality in patients diagnosed with high risk prostate 
cancer in Sweden. 
 
Material and Methods 
In this population based cohort study, we used data from a comprehensive database 
(PCBaSe Sweden) including prostate cancer patients identified in the NPCR of Sweden 
between 1997 and 2006 with additional information retrieved from other population based 
registers. High risk prostate cancer was defined as clinical T3 tumor, and/or Gleason Score 
8–10 and/or prostate specific antigen levels of 20–50 ng/mL. Logistic regression with odds 
ratios (OR), Cox regression with hazard ratios (HR), and Fine and Gray‟s competing risk 
regression with subdistribution hazard ratios (sHR) were used to assess associations between 
socioeconomic status, bone scan, intention to treat, curative treatment, and mortality 
adjusted for comorbidity, age, calendar period and clinical subgroups. Socioeconomic status 
was based on occupation and categorized into five levels; blue-collar workers, farmers, self-
employed, lower white-collar workers and higher white-collar workers. 
 
Results 
A total of 17,522 patients diagnosed with high risk prostate cancer between 1997 and 2006. 
Of these, 6,681 (38.1%) were blue-collar workers. Patients registered as blue-collar workers 
were older at diagnosis and had a higher comorbidity burden compared to higher white-
collar patients. Figure 6.3.1 a) illustrates the likelihood to undergo a bone scan by 
socioeconomic status, adjusted for calendar period, age at diagnosis, clinical subgroups and 
comorbidity. A bone scan was significantly more likely to be performed in higher white-
collar workers compared to blue-collar workers (OR 1.30; 95% CI 1.21 to 1.40). 
 
Among patients with high risk prostate cancer free from metastases based on the results 
from the bone scan, differences in intention to treat between higher white-collar and blue-
collar workers remained after adjustment for potential confounders (OR 1.43; 95% CI 1.28 
to 1.57) (Figure 6.3.1 b). 
 
A total of 4,304 (47.9%) men free of metastases underwent curative treatment. In men with 
higher white-collar background, 34.5% underwent radical prostatectomy compared to 28.3% 
of blue-collar worker patients. Following adjustment for demographic and clinical 
characteristics, patients from the higher white-collar group were more likely to undergo 
radical prostatectomy compared to blue-collar patients (OR 1.29; CI 95% 1.10 to 1.47) 
(Figure 6.3.1 c). 
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Figure 6.3.1 Likelihood of a) bone scan, b) intention to treat, and c) radical prostatectomy in patients 
diagnosed with high risk prostate cancer 
 
In men that underwent curative treatment following a bone scan, the cumulative probability 
of prostate cancer death was 10.0% (95% CI 6.7 to 13.3%) amongst higher white-collar 
workers and 14.4% (95% CI 11.2 to 17.8%) in blue-collar workers (Figure 6.3.2). In the 
same treatment subgroup of patients, a social gradient in both overall and cause-specific 
mortality persisted after adjustment for potential confounders (higher white-collar versus 
blue-collar workers; overall HR 0.76; CI 95% 0.60 to 0.97, cause-specific sHR 0.70; CI 95% 
0.49 to 0.99). 
 
 
 
Figure 6.3.2 Cumulative probability of prostate cancer death by socioeconomic status in patients diagnosed 
with high risk prostate cancer free from metastases that underwent curative treatment 
 
Conclusion 
We conclude that socioeconomic disparities in management and mortality in men with high 
risk prostate cancer exist also within the setting of a National health care system aiming to 
provide care on equal terms to all residents. 
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6.4 Study IV: Comorbidity, treatment and mortality – A population based cohort 
study of prostate cancer in PCBaSe Sweden 
 
Introduction 
Increased longevity will lead to aging populations and a higher prevalence of men with 
prostate cancer. Since the comorbidity burden increases with age, it will be increasingly 
important to consider co-existing disease in the clinical management of cancer. We aimed to 
examine in detail the influence of comorbidity on treatment decisions and mortality using a 
competing risk approach in men diagnosed with prostate cancer. 
 
Material and Methods 
For the purpose of the present study, we used information available in PCBaSe Sweden, a 
prostate cancer database of men diagnosed with prostate cancer identified in the National 
Prostate Cancer Register of Sweden, with record-linkages to the Swedish Cancer Register, 
the National Patient Register and the Cause of Death Register. The Charlson comorbidity 
index (CCI) was used to assess the burden of co-existing disease for each patient, 
categorized into three comorbidity levels; CCI 0 for no comorbidity, CCI 1 for mild and 
CCI 2+ for severe comorbidity. Binary logistic regression was used to assess associations 
among CCI and treatment modalities with odds ratios (OR) and 95% confidence intervals 
(CI). Cumulative and conditional incidence functions were derived to assess associations 
between CCI and mortality, while the Cox regression with hazard ratios (HR) and the Fine 
and Gray‟s competing risk regression with subdistribution hazard ratios (sHR) were used to 
adjust for demographic and clinical characteristics. 
 
Results 
A total of 77,536 men were diagnosed with prostate cancer between 1997 and 2006. Of 
these, 21,915 (28.3%) patients had at least one other medical condition, recorded in the 
National Patient Register. Prostate cancer patients with no record of comorbidity were 
younger at diagnosis, and were more often detected by a health control (28.3%) compared to 
patients with severe comorbidity (12.1%). 13,428 (25.3%) men without comorbidity had low 
risk prostate cancer compared to 1,792 (14.7%) men with severe comorbidity.  
 
Among patients diagnosed with low risk prostate cancer, 5,975 of the 13,245 (45.1%) with 
no record of comorbidity underwent radical prostatectomy compared to 1,399 (18.3%) with 
severe comorbidity. In the same clinical risk group, the distribution for surveillance as the 
primary choice of management between patients without and with severe comorbidity was 
38.9% and 63.3%, respectively. Following adjustment for age and calendar period of 
diagnosis, patients with severe comorbidity were less likely to undergo radical prostatectomy 
(OR 0.51; 95% CI 0.43 to 0.60), while the likelihood of surveillance was significantly higher 
in patients with severe comorbidity (OR 1.50; 95% CI 1.32 to 1.70). 
 
In patients diagnosed with high risk prostate cancer, gonadotropin-releasing hormone 
analogues (GnRH) were the most common mode of treatment independent of comorbidity 
burden. In the same clinical subgroup, radiotherapy was more common (range 7.7% to 
21.3%) than radical prostatectomy (range 3.0% to11.2%) regardless of comorbidity burden. 
Following adjustment for age and calendar period, patients with severe comorbidity were 
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less likely to receive radiotherapy or to undergo radical prostatectomy compared to those 
with no concomitant disease (radiotherapy, OR 0.57; 95% CI 0.49 to 0.66; radical 
prostatectomy, OR 0.51; 95% CI 0.41 to 0.65). In high risk prostate cancer, or distant 
disease, patients with severe comorbidity were less likely to be treated with anti-androgens 
compared to patients with no record of comorbidity. Patients in all clinical subgroups with 
severe comorbidity were more likely to receive GnRH compared to men free of comorbidity 
(p<0.01), with the exception of patients with distant metastases. 
 
 
Figure 6.4.1 Cumulative probability of death by Charlson comorbidity index 
 
Figure 6.4.1 shows the cumulative probability of mortality by comorbidity burden using 
three different endpoints. When considering mortality from competing causes, the 
probability of prostate cancer mortality was lower in men with severe comorbidity compared 
to those with no registered concomitant disease, but was higher for mortality from other 
causes. In the Kaplan-Meier estimates of prostate cancer mortality, the estimate was 
consistently higher in patients with severe comorbidity. 
 
Using the Cox model and Fine and Gray‟s competing risk regression, and following 
adjustment for age at diagnosis, calendar period, and clinical risk group, patients with severe 
comorbidity had a higher all-cause and competing cause mortality, but not prostate cancer 
specific mortality (all-cause HR 1.99; 95% CI 1.93 to 2.05; competing cause sHR 2.66; 95% 
CI 2.56 to 2.78; prostate cancer specific sHR 0.98; 95% CI 0.93 to 1.03). In patients with 
low risk prostate cancer and severe comorbidity, the risk of competing cause mortality was 
more than threefold higher in patients with severe comorbidity compared to men without 
comorbidity (sHR 3.39; 95% CI 3.00 to 3.84). Prostate cancer specific mortality was not 
elevated in any clinical risk group among patients with severe comorbidity. 
   
Figure 6.4.2 illustrates the cumulative probability of prostate cancer death, given no death 
from competing causes, by clinical risk group and comorbidity burden. In all clinical risk 
groups, the conditional prostate cancer death was higher in patients with severe comorbidity 
in contrast to patients with no record of coexisting disease (p<0.01). The difference in 
conditional prostate cancer mortality by comorbidity burden increased throughout follow-
up, except in distant metastatic disease.  
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Figure 6.4.2 Cumulative probability of prostate cancer mortality, given no death due to other causes, by 
clinical risk groups, treatment modalities and comorbidity burden 
 
Conclusion 
The present findings indicate that the presence of concomitant disease is considered in the 
treatment decisions for patients with prostate cancer. Patients with severe comorbidity 
received curative treatment less often, and had a higher all-cause and competing cause 
mortality, but lower prostate cancer specific mortality. However, in conditional probability 
prostate cancer mortality analyses given no death from other causes, men with severe 
comorbidity had a higher prostate cancer specific mortality. 
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7 DISCUSSION 
 
7.1 Methodological considerations 
 
In general the findings reported in this thesis were in line with results from most previous 
studies in this area. There was also a consistency in findings with regard to the role of 
socioeconomic factors between our different studies. However, all observational studies are 
more or less prone to errors. Two main types of error are present in epidemiological studies: 
systematic and random errors. Bias is another term for systematic error. A study can be 
biased because of the way the subjects have been selected, the way the study variables have 
been measured or confounding factors. The validity of an observational study depends on 
the degree of systematic error, and the concept of validity is usually discussed in terms of 
internal and external validity. Random errors result from the play of chance and are related 
to the concept of precision. The precision of a result is decided by the level of random 
errors. Random errors would be reduced to zero if a study becomes infinitely large. 
 
  
7.1.1 Internal validity 
 
A strong internal validity means measurements of the exposure and the outcome variables 
are reliable, and in studies of causation, a strong internal validity justifies the causally links 
between the exposure and outcome variables 148. There are three broad categories of threats 
to internal validity that must be considered: selection bias, information bias and 
confounding, which once introduced into a study are difficult to remove.   
 
Selection bias is a systematic error that in retrospective cohort studies may occur if the risk 
of outcome influences the probability of being included in the exposed (or unexposed) 
group, or influences the way in which exposure is defined 148. In the present studies, virtually 
all lung and prostate cancer cases in the regions under study were included. In Sweden, the 
completeness of the quality registers for lung cancer in central Sweden, and prostate cancer 
in Sweden exceed 95% in comparison to cases registered in the Swedish Cancer Register. 
However, a small proportion of all cancers remain undetected during life or are not 
registered in the Swedish Cancer Register, especially for cancer sites with poor prognosis 
such as lung cancer 58, and that are detected for the first time at autopsy. Lung cancer cases 
detected at autopsy were only registered in the first calendar period in the Regional Lung 
Cancer Register (1995-2000), and autopsy cases are not included in the National Prostate 
Cancer Register of Sweden. Furthermore, it cannot be ruled out that socioeconomic status 
might affect the probability that a malignancy remains undetected until after death. 
 
Information bias occurs when information on exposures and outcomes are erroneous 148. 
In all our studies exposure information was retrieved from population based registers of 
high quality, which reduced the risk of misclassification. Differential misclassification of 
exposure occurs if the misclassification is dependent on the outcome, or non-differential if it 
is unrelated to the outcome. Differential misclassification is problematic and can either 
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exaggerate or underestimate an effect, whereas non-differential misclassification tends to 
bias an association towards the null or no-effect value.  
 
The different indicators of socioeconomic status used as exposures in the present thesis 
have different properties and limitations. In study I, level of education was used as the main 
indicator of socioeconomic status. Level of education has the advantage of being relatively 
easy to measure, it is generally uncontroversial (as opposed to other measurements of 
socioeconomic status such as income), it can capture socioeconomic status in the early 
stages of a subjects life, it is broadly stable throughout the course of life and usually predates 
and to some degree determines employment and the ability to earn income 149 150. Level of 
education has also been shown to be a good indicator of social position in relation to health 
and survival 151, particularly since it may also reflect dimensions of health awareness and 
ability to access and navigate the health care system 152. A disadvantage of education is that it 
is generally fixed in adult life and for some countries it shows little variation. Also, it can be 
affected by birth cohort effects in that educational systems change over time. Also, 
education level is not always readily transferable between countries, cultures and educational 
systems and it only provides information on quantity rather than educational quality 149 150.  
 
In study II, based in South East England, an area-based measurement of deprivation was 
used. The income domain of the Indices of Deprivation has been found to perform better 
than earlier area-based measurements used in the United Kingdom 153. One of the key 
criticisms of the present indices has been the inclusion of health domain and the concern of 
mathematical coupling, the phenomenon whereby two variables will inevitable correlate if 
they share elements of each other. In study II, the area-based measurements were used as 
indicators for the deprivation of individual lung cancer patients at the time of diagnosis, an 
approach that is likely to lead to an underestimation of social differences in survival 154. In 
addition, the variability in socioeconomic status based on area characteristics will always be 
smaller than that of the individual factor, that is, the lowest value in the area income will 
always be higher than the lowest individual income, and vice versa for the highest income 155.  
 
In study III, occupation which has the advantage of being widely available in routine Census 
data, was used as an indicator for socioeconomic status. Occupation represents a major link 
between education and income, such that education determines occupation which in turn is 
related to income. Furthermore, occupation is not only a major influential factor on the 
stratification of society, but it is also a major influence on the structure of an individual‟s life 
149 150 156. However, the method of coding occupations to different social classes is arbitrary 
and somewhat subjective where each stratum can be heterogeneous in terms of education 
and income. Furthermore, a significant proportion of the population will not be assigned 
socioeconomic status (including unemployed, retired people, students), and occupational 
classifications also struggle to keep up with continually evolving and more complex jobs. In 
study I and III, historical data were used to assess the highest lifetime socioeconomic status 
in patients diagnosed after retirement. 
 
In study IV, we used the Charlson comorbidity index (CCI) as the exposure variable and an 
indicator for comorbidity burden, while it was used as a covariate in study II and III. The 
CCI has been validated in several studies 157-159, but it does not, however, permit 
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distinguishment between the mildest and the most severe cases in each category of 
comorbidity burden, since the index is based on discharge diagnosis from inpatient 
admissions only. Furthermore, patients who were treated for their medical condition solely 
by their general physician score 0 in the index, which could lead to an underestimation of 
comorbidity burden when using only the CCI as an exposure variable. 
 
In study II, where treatment was used as an outcome, it was based on registration of „Yes‟ or 
„Unknown‟.  However, it was unclear if „Unknown‟ meant unknown or no active treatment. 
The most affluent patients were more likely to have a registered „Yes‟, which is likely to 
reflect that they were more likely to undergo treatment than the most deprived patients. 
Patients with an „Unknown‟ registration had a poorer prognosis which may indicate that they 
received no active treatment.  
 
Information bias may also occur if follow-up is incomplete. In study II, based on data from 
South East England, complete follow-up was available regarding vital status (alive, 
emigration, or dead). In the Swedish studies there was complete follow-up data on all 
patients with information based on vital status, and cause of death information retrieved 
from the Cause of Death Register. The reliability of death certificates for prostate cancer 
patients has been shown to be high 160. However, it cannot be excluded that the validity of 
cause of death information is lower for the elderly, and particular among old patients with 
severe comorbidity burden. Thus, the validity may vary between age groups. 
 
In study I, we observed a lower diagnostic intensity in lung cancer patients with low 
education. Thus, some patients with advanced disease might have been misclassified as 
having early stage disease, which is known as the Will Rogers phenomenon 161. Inaccurate 
staging may have led to a poorer stage-specific survival for the most disadvantaged patients. 
 
Confounding is defined as the influence of factors that are associated with the exposure 
and in themselves predict the likelihood of the outcome, but that are not intermediate steps 
in the pathway from exposure to outcome 148. Lack of relevant information on confounding 
factor is common in retrospective studies. In the studies included in the present thesis 
information was available on potential confounding factor such as age at diagnosis, 
performance status, comorbidity and smoking history. Furthermore, we had information on 
clinical characteristics and planned or received initial treatment. However, these factors may 
also be intermediate steps in the pathway between socioeconomic status and survival, and 
thus it is unclear whether adjustment for these factors always is appropriate. Nonetheless, 
they might help to explain the survival difference between patients with low and high 
socioeconomic status. In study II, we calculated the contribution of each covariate on the 
relative change of the hazard ratio between the most deprived and the most affluent 
patients. With that approach, the most important contribution was found for initial 
treatment. Furthermore, analyses were stratified on stage at diagnosis and on treatment 
decisions to minimize possible confounding by indication.   
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7.1.2 Precision 
 
Precision is defined as the degree to which a measurement is free of random error 148. High 
precision of estimates makes chance a less likely explanation of the findings. Sample size, 
prevalence of exposure and extent of exposure misclassification are important determinants 
of precision. We considered a significance level of five percent in all studies, and used 
confidence intervals and p-values as a measure of the precision of our results. A narrow 
confidence interval implies a small variability in the estimate, and if the confidence interval 
did not include the null value (or one with odds or hazard ratios) it is unlikely that the 
findings will be the result of chance. The significance testing should be considered as a 
measure of chance, and not a proof of association. When several associations between 
exposure and outcome are addressed simultaneously, the potential role of chance in 
producing a particular result should not be ignored. There is also a possibility that null 
results will be due to chance, and that associations between an exposure and an outcome 
existed that we did not have the statistical power or appropriate tools to discover. While 
studies in the present thesis included virtually all incident cancer cases during the period 
under study, the interpretation of results in some subgroups may have been hampered by a 
small number of events.  
 
 
7.1.3 External validity 
 
External validity addresses the ability to generalize the studies to other settings 148. Assuming 
that bias, confounding and the roles of chance have not seriously affected our results we can 
assess the applicability of our findings to other populations. The studies included in the 
present thesis were all based on population based data, and all included men and women 
residing in well-defined regions with similar health care systems and quality of care. 
However, the generalizability of our results may be limited by effect modification. An effect 
modification occurs when the effect of an exposure varies in different subgroups of the 
population. In study I and II, we observed varied associations by different stages at 
diagnosis. Thus, we cannot generalize the observed social differences in survival in early 
stage disease to any other population without information on stage at diagnosis. 
Furthermore, in the first study, immigrants were excluded which makes it more difficult to 
generalize the results to regions in Sweden where the proportion of immigrants is high. Also, 
the interpretations of the results from Study II, based on data from South East England, 
may not be applicable to other regions of England. Study III and IV included prostate 
cancer patients from the whole of Sweden, and the results should thus be applicable to all 
men in Sweden. Because of national differences between health care systems, results from 
this thesis may not be applicable to patient groups managed in other countries.  
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7.2 Main findings 
 
7.2.1 Study I and II: Socioeconomic status and lung cancer 
 
We found evidence of social differences in the clinical management and survival in patients 
diagnosed with lung cancer both in South East England (Study II) and in central Sweden 
(Study I). In central Sweden, we observed social variations in waiting time from referral to 
date of diagnosis and higher diagnostic intensity among patients with high education. In 
both the Swedish and the English study, socioeconomic status was associated with 
comorbidity burden. We found no evidence of social differences in stage at diagnosis in 
either study. However, in both settings, there were social variations in treatment intensity, 
most pronounced in early stage disease. In the Swedish study, we found social differences in 
lung cancer survival that were restricted to women in early stage disease. The English study 
found social gradients in survival in both early stage and advanced disease in both sexes. 
Differences in early stage survival remained throughout follow-up, whereas in advanced 
disease, variations were confined to the period immediately after diagnosis. 
 
Findings from a British study showed that older age and being unmarried were factors 
associated with longer diagnostic delays in lung cancer 162. A recent Danish population based 
study documented associations between level of education and time between referral and 
diagnosis 79, findings which corroborate with our Swedish results 163. While waiting time may 
not affect prognosis, delays are likely to be associated with anxiety and stress. It has been 
suggested that multidisciplinary management can reduce delays, particularly with regard to 
the time between referral and initial treatment 164.  
 
In 2001, Brewster et al. reported that the most deprived patient group with non-small cell 
lung cancer (NSCLC) were more likely to be diagnosed with localized disease 78, while no 
such social differences in stage at diagnosis were observed in a large population based study 
in Canada 77, findings which supports our results. However, Danish investigators reported 
that lung cancer patients with high education were less likely to be diagnosed with stage 
IIIB-IV disease 79, which is in line with results from a study from United States 165. We found 
that patients with low socioeconomic status were more likely to have co-existing disease, 
which is supported by findings from Denmark 79,  the Netherlands 45 and a Scottish study 166. 
Also, in accordance with our results, the Danish study found that patients with severe 
comorbidity were more likely to be diagnosed with early stage disease which may reflect that 
the lung cancer was detected in the course of seeking medical care for other conditions. 
 
In accordance with results from earlier studies conducted in United States and England, we 
found evidence of variations in management by socioeconomic status 85 167-170. In early stage 
disease, we observed social gradients in the likelihood to undergo surgical resection, 
independent of calendar period, sex, age, histology, smoking history and performance status 
in the Swedish study, and sex, age, and comorbidity burden in the English study. While 
performance status and comorbidity were taken into account in the analyses, we cannot 
exclude that poorer general health and surgical risks in the most deprived groups influenced 
the choice of treatment 171. In our studies, socioeconomic status was not statistically 
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significant associated with the likelihood of receiving radiotherapy, but it was in regard to 
receive on chemotherapy. An earlier study conducted in South East England found a 
significant social gradient in that chemotherapy was more frequently used in the highest 
socioeconomic groups, which corresponds to result from a study in United States 167 172. 
Another population based study found that patients with high education were more likely to 
receive radiotherapy than to undergo surgery 173. 
 
Our findings of social variations in lung cancer survival are supported by some 72 88 89 174 175, 
but not all investigators 40 176. We found no differences in crude survival among Swedish lung 
cancer patients when number of persons in the household was used as indicator of social 
support, results which are supported by at least one other lung cancer study, in which 
marital status was used as an indicator for social support 177. When using level of education 
and a deprivation index as socioeconomic indicators, we observed the largest social 
differences in early stage disease, supporting the notion that the role of socioeconomic 
factors is most important for cancer sites with good prognoses where treatment decisions 
can prolong survival 178. In the Swedish study, the social inequalities in survival observed 
among women in early stage were independent of age at diagnosis, histology, performance 
status, smoking history and treatment factors. In the English study, observed gradients in 
cancer survival were independent of sex, age at diagnosis, comorbidity, and treatment. 
Furthermore, detailed analysis of the English data revealed that variations in treatment 
between the most deprived and the most affluent patients contributed most to the social 
differences in survival.  
 
 
To our knowledge, our English study is the first that presents both absolute and relative 
measures between socioeconomic groups throughout follow-up. In early stage NSCLC, the 
gap in mortality rates and survival between the most deprived and the most affluent group 
persisted during follow-up, while in more advanced disease, no social differences were seen 
five months post diagnosis. Social differences in short-time survival have been previously 
been reported for colorectal patients in England 179. It appears unlikely that these findings 
could be attributed to the registration system in England, i.e. variations between social 
groups. The observed social variations in lung cancer survival may reflect social differences 
with regard to the tumor and host characteristics as well as access to care provided by the 
health care system. 
 
 
7.2.2 Study III: Socioeconomic status and prostate cancer 
 
In Study III, we demonstrated that men with high socioeconomic status diagnosed with high 
risk prostate cancer more often underwent an extensive work-up, received active treatment 
and had better outcomes, compared to men with low socioeconomic status. A bone scan 
was performed more often among white-collar workers. The likelihood of intention to treat, 
to receive curative treatment and to undergo radical prostatectomy, was also more common 
in this group. In the subgroup of men with no signs of metastatic disease that received 
curative treatment, higher white-collar workers had a lower prostate cancer and all-cause 
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mortality following adjustment for calendar period, age at diagnosis, clinical characteristics 
and comorbidity. 
 
Results from several epidemiological studies show that the increasing incidence of prostate 
cancer in the recent decades reflect a more wide spread use of prostate specific antigen 
(PSA) testing 180 181. In 2005, 28 percent of incident prostate cancer cases in Sweden were 
detected based on the PSA test, while the corresponding proportion in 2009 was 42 percent 
65. The trend towards early detection of prostate cancer has led to efforts to identify men for 
whom bone scan can be omitted 182-184. However, there will always be a certain proportion of 
patients that harbor bone metastases at first diagnosis 182 185 186. In patients diagnosed with 
high risk prostate cancer (defined as clinical T3 tumor, and/or Gleason score 8-10, and/or 
PSA 20-50 ng/mL), guidelines, including those in Sweden, recommend a metastatic work-up 
113 187.     
 
A bone scan has a high accuracy of detecting metastatic disease in patients with high risk 
prostate cancer 113, but is an expensive and time-consuming method of imaging. To our 
knowledge, our study is the first that has reported social variations in the likelihood of 
undergoing bone scan following a prostate cancer diagnosis, differences which remained 
after adjustment for calendar period, age at diagnosis, clinical characteristics and 
comorbidity. However, our study lacked information on symptoms, such as back pain, that 
suggest the presence of metastases and that therefore justify performing a bone scan. Thus, 
it cannot be excluded that our findings reflect differences in reporting symptoms between 
socioeconomic groups. Moreover, it should be acknowledged that even with a negative 
result from the bone scan, some high risk patients might still harbor skeletal metastases that 
remain undetected by conventional scintigraphy 188-190. 
 
In patients with high risk prostate cancer free of metastases, decision regarding curative 
treatment should be based on the patient‟s general health and life expectancy, rather than the 
chronological age 191. We found that higher white-collar workers were more likely to be 
treated with curative intent, than blue-collar workers 192. Social variations in treatment have 
previously been reported in studies conducted in Switzerland 120, the United States 193 and 
the United Kingdom 118. However, none of these studies included information on 
comorbidity or focused on high risk prostate cancer. The addition of local radiotherapy to 
endocrine therapy has been shown to reduce the ten year prostate cancer specific mortality 
by 50 percent 194. However, no randomized trial has evaluated the effect of radiotherapy on 
radical prostatectomy in high risk disease. Observational studies have found that both 
treatment modalities have potential benefits and toxicities that must be taken into 
consideration in relation to the patient‟s general health status and clinical characteristics 195. 
We found that higher white-collar workers were more likely to undergo radical 
prostatectomy than radiotherapy, independent of calendar period, age at diagnosis, clinical 
characteristics and comorbidity. Many clinically prostate tumors categorized as high risk are 
pathologically confined to the prostate, which may have been the case in the same patients 
that underwent radical prostatectomy. Furthermore, patients with high socioeconomic status 
may be more likely to accept the risks associated with surgical resections 196. 
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In men who underwent curative treatment and who were free of metastatic disease as 
determined by a bone scan, higher white-collar patients had both a lower all-cause mortality, 
but also a lower prostate cancer specific mortality than blue-collar workers 192. Social 
gradients in survival have previously been observed both for prostate cancer specific and 
overall survival 118 120 193. However, no earlier studies have found these gradients in high risk 
prostate cancer. Results from previous studies have demonstrated that positive surgical 
margins in radical prostatectomy affect prostate cancer specific survival 197. Similarly, 
administrative techniques and dosimetry in radiotherapy, both of which are independent 
quality control indicators, are known to predict biochemical failure and the likelihood to 
develop distant metastases 198 199. The social difference in survival after therapy may thus be 
explained by clinical factors not evaluated in the present study, such as biopsy tumor burden. 
Finally, since we observed social differences in initial treatment, it can also be hypothesized 
that social variations exist with regard to subsequent treatment, which we were unable to 
explore. 
 
 
7.2.3 Study IV: Comorbidity and prostate cancer  
 
In study IV, we found that patients diagnosed with prostate cancer with severe comorbidity 
were more often diagnosed with low risk prostate cancer and were less likely to receive 
curative treatment compared to patients with no record of co-existing disease. Following 
adjustment for calendar period, age at diagnosis and clinical characteristics, patients with 
severe comorbidity had a higher all-cause and competing cause mortality. In analyses of 
conditional prostate cancer mortality, i.e. analyses given no death due to competing causes, 
men with severe comorbidity had higher prostate cancer mortality, a finding which was most 
pronounced in men with more advanced prostate cancer. 
 
Our finding of a lower proportion of low risk disease in patients with severe comorbidity 
reflects, in all likelihood, a low screening intensity in this group. Several studies have 
indicated that men diagnosed by PSA testing are younger, healthier and more likely to have a 
high socioeconomic status than the background population in the same age groups 45, 
factors that are all associated with a lower comorbidity burden prior to the prostate cancer 
diagnosis. 
 
Severe comorbidity influences quality of life and life expectancy. Curative treatment such as 
radical prostatectomy is usually performed only in men with a life expectancy of more than 
ten years 200. Because of the natural history of low risk prostate cancer, the majority of 
patients will not die from their disease within 10 to 15 years from diagnosis 201 202. We found 
that the majority of patients with low risk disease and severe comorbidity were put on 
surveillance. However, almost one fifth (18.3%) of men with low risk disease and severe 
comorbidity underwent radical prostatectomy, that is associated with a risk of morbidity that 
can significantly affect quality of life 203-205. It has previously been reported that men with low 
risk prostate cancer are often over treated 206, and that men with severe comorbidity and low 
risk prostate cancer should be considered conservative management, given their exceedingly 
high risk of death from other causes 207. However, a study based on the NPCR of Sweden 
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concluded that 30-days mortality was very low following radical prostatectomy in localized 
prostate cancer patients 208. 
 
Alibhai pointed out that in men who receive Gonadotropin-releasing hormone (GnRH), the 
toxicity will be higher in patients with severe comorbidity 209 210. However, the use of GnRH 
as the primary choice of treatment in patients with localized disease has decreased in Sweden 
over time, results which are essentially in accordance with data in United States 209 211. In the 
present study, surveillance or hormonal treatment was the treatment of choice in all clinical 
risk groups in men with severe comorbidity, which indicates that general guidelines are 
adhered to and that comorbidity is considered in treatment decisions 212. Earlier results have 
also indicated that comorbidity seems to be integrated into treatment decisions for prostate 
cancer 213-216. However, results from some studies have suggested that patient age and the 
clinician‟s experience are the primary determinants for treatment decisions, and not 
comorbidity burden 217 218. 
 
In the present study, we found an increased risk of all-cause and competing cause mortality, 
but not prostate cancer specific mortality in patients with severe comorbidity in all clinical 
risk groups. Our findings were expected, and several other investigators have found 
associations between comorbidity and mortality in prostate cancer patients 158 207 219-222. The 
relative gap in all-cause and competing cause mortality between patients with no record of 
comorbidity and severe comorbidity was largest in low risk disease, which is in line with 
recent data from the United States 223. In a competing risk setting, a randomized trial showed 
no statistically significant increased risk of prostate cancer mortality in patients with at least 
one severe comorbidity 224, which also supports our findings.   
 
The association between comorbidity and all-cause and competing cause mortality is likely to 
be explained primarily by co-existing diseases. However, it cannot be excluded that the 
prostate cancer related treatment also negatively influenced mortality 225 226. We observed 
increased conditional prostate cancer mortality in patients with severe comorbidity. Stratified 
analyses revealed that the gap in conditional prostate cancer mortality between patients with 
severe comorbidity and free of comorbidity was most pronounced in more advanced 
prostate cancer.  
 
 
7.3 General discussion and future perspectives 
 
Taken together, the result of the present thesis shows that socioeconomic status influences 
not only clinical management, but also survival in patients diagnosed with lung cancer both 
in central Sweden and South East England, as well as in patients with prostate cancer in 
Sweden, using different indicators for socioeconomic status. Furthermore, comorbidity 
burden influenced both treatment decisions as well as outcomes in prostate cancer. The 
mechanisms underlying socioeconomic differences in management and survival remain 
unclear, but may be discussed in relation to at least three dimensions: factors relating to the 
tumor, the host and the health care system. 
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Tumor characteristics include both biological features of a tumor and stage at diagnosis. 
The histological type is an important biological feature of a tumor and may also be a 
prognostic factor. For example, lung cancer patients diagnosed with small cell lung cancer 
experience poorer survival than patients diagnosed with non-small cell lung cancer. Small 
cell lung cancer has been shown to be strongly associated with tobacco smoking, which is 
more common in lower socioeconomic groups. It has been suggested that part of the lower 
survival observed in lower socioeconomic groups may be explained by differences in 
histological subtypes. In study I, the study population was restricted to patients with non-
small cell lung cancer, whereas in study II, both non-small cell and small cell lung cancer 
were included. Thus, the observed social differences in survival in more advanced stage lung 
cancer in study II, but not in study I, may be related to distribution of histological subtypes. 
Prostate cancer is histologically a more homogenous cancer form with more than 99 percent 
of cases being adenocarcinomas. A more advanced stage at diagnosis has been put forward 
as a key explanation for a poorer cancer survival in low socioeconomic groups. However, we 
found no evidence of social differences in stage at diagnosis in lung cancer. Study III was 
restricted to high risk prostate cancer, but no differences in clinical subgroups were 
observed between social groups. In conclusion, it seems unlikely that the observed social 
differences in survival could be fully explained by lead time bias, if stage at diagnosis and 
clinical subgroups are used as indicators for lead time. 
 
Host characteristics represent another possible explanation for social differences in 
survival. Deprived patient groups with poor health may have an impaired host resistance, 
facilitating rapid tumor growth and spread. Also, life-style factors that have been associated 
with low socioeconomic status include physical inactivity, poor nutritional status, obesity, 
alcohol consumption and tobacco smoking. All these factors may be associated with poorer 
outcomes. Similar to findings in earlier studies, we found that patients with low 
socioeconomic status had a higher comorbidity burden at diagnosis or a poorer performance 
status at date of initial treatment. In our studies, adjustment for comorbidity or performance 
status did not eliminate the survival differences according to socioeconomic status. Also 
survival differences remained when analyses were restricted to patients with no record of 
comorbidity. Tobacco smoking leads to a poorer health status, but was not quantifiable in 
our comorbidity score. In Study I, social inequalities in survival in early stage lung cancer 
remained following adjustment for self-reported tobacco smoking. Stressful life events, and 
lack of social support have also been found to be more common among groups with low 
socioeconomic status, but the possible prognostic role of these factors in lung and prostate 
cancer patients remains incompletely understood. We found no differences in survival 
among Swedish lung cancer patients when the number of persons in the household was 
used as indicator for social support. The observed social differences in survival in the 
present thesis could not be fully explained by host characteristics such as comorbidity 
burden, performance status and smoking history.  
 
The health care system represents a key determinant for cancer outcomes. We found 
evidence of social differences in both diagnostic and treatment intensity among lung and 
prostate cancer patients. Social differences in treatment explained most of the observed 
inequalities in lung cancer survival in study II. Possible explanations include differences in 
rapport between the physician and the patient, demands and expectations from the patient 
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and the communication skills of both parties. There may also be social differences in 
acceptance of compliance with treatments such as adjuvant therapies. Economic barriers to 
accessing a cure are unlikely to explain the findings in our Swedish studies. In conclusion, 
our findings may reflect aspects of physician-patient interaction and a subtle bias towards 
more action on behalf of the physicians when managing high socioeconomic status patients. 
 
Taken together, the results of the present thesis show that social differences exist in the 
clinical management and survival of patients diagnosed with lung cancer in central Sweden 
and in South East England, as well as in patients diagnosed with prostate cancer in Sweden. 
Furthermore, we found that comorbidity was considered in management decisions and 
influenced survival in prostate cancer. Our findings raise the importance of continuous 
monitoring of quality and equality of cancer care using information available in quality 
registers on cancer and in other health care databases. Equality in cancer management and 
survival needs to be addressed, not only in relation to socioeconomic status, but also with 
regard to ethnicity, age and region of residence. 
 
Also, further research is needed to improve the understanding of the relative contribution of 
tumor characteristics, the host, and the health care provider, that can explain the observed 
social differences in management and survival. In this context, more detailed information on 
comorbidity would be of interest both in relation to socioeconomic status and to the role of 
co-existing disease.    
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8 CONCLUSIONS 
 
 
 We found evidence of a social gradient in the clinical management and survival in 
patients diagnosed with lung cancer both in central Sweden and in South East 
England. Both shorter waiting time from referral to date of diagnosis and a higher 
diagnostic intensity were observed in lung cancer patients with high socioeconomic 
status, while no social differences in stage at diagnosis were observed in Sweden or 
England.  
 
 Lung cancer patients with high socioeconomic status were more likely to undergo an 
active treatment, most pronounced in early stage disease. The observed social 
inequalities in lung cancer survival were most pronounced in early stage disease, and 
could not fully be explained by comorbidity burden and smoking history. In South 
East England, the social gradients in survival in early stage disease remained 
throughout follow-up, whereas in advanced disease, variations in survival were 
confined to the period immediately after diagnosis. 
 
 White-collar workers diagnosed with high risk prostate cancer underwent more often 
an extensive work-up, received active treatment and had better outcomes compared 
with blue-collar workers. A bone scan was performed more often among white-
collar workers. The likelihood of intention to treat, reception of curative treatment 
and radical prostatectomy treatment was also more common among these patients. 
In the subgroup of men with no signs of metastatic disease that received curative 
treatment, higher white-collar workers had a lower all-cause as well as prostate 
cancer specific mortality. 
 
 Patients diagnosed with prostate cancer with severe comorbidity were less often 
diagnosed with low risk prostate cancer and received less curative treatment than to 
patients with no co-existing disease. Patients with severe comorbidity had a higher 
all-cause and competing cause mortality, but not prostate cancer specific mortality. 
In analyses given no death due to competing causes, men with severe comorbidity 
had higher prostate cancer mortality, foremost in men with more advanced prostate 
cancer. 
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9 SWEDISH SUMMARY (Svensk sammanfattning) 
 
 
Resultat från epidemiologiska studier från olika delar av världen har pekat på förekomsten av 
sociala skillnader i canceröverlevnad. Det är känt att många patienter vid sidan av sin 
cancersjukdom också lider av andra sjukdomar. Studierna i denna avhandling undersöker 
eventuella skillnader mellan socioekonomiska grupper avseende handläggningsintensitet och 
överlevnad bland patienter med lungcancer i Mellansverige och sydöstra England, och 
patienter med högrisk prostatacancer i Sverige. Dessutom studeras om samsjuklighet hos 
svenska prostatacancerpatienter påverkar val av behandling och dödlighet. 
 
Studierna i avhandlingen baserades på information från det Regionala Lungcancerregistret i 
Uppsala-Örebroregionen, Thames cancerregister i Sydöstra England och forskningsdatabasen 
PCBaSe Sweden, en informationskälla baserad på Nationella Prostatacancerregistret med 
länkningar till bl.a. LISA-databasen, Cancerregistret, Patientregistret och Dödsorsaksregistret. 
Utbildningsnivå, ett Jämlikhetsindex, och ett socioekonomiskt index baserat på yrke användes 
som de huvudsakliga indikatorerna för socioekonomisk status. I syfte att skatta grad av annan 
sjukdomsbörda användes Charlson´s komorbiditetsindex. Samband mellan socioekonomisk 
status, komorbiditet, handläggning och risken för död analyserades med bland annat logistisk 
regression och överlevnadsanalys. 
 
Vi fann förekomst av sociala skillnader avseende väntetid och diagnostisk intensitet bland 
patienter med lungcancer i Mellansverige.  Inga sociala gradienter i stadium vid diagnos 
observerades vare sig i Mellansverige eller Sydöstra England. I båda regionerna erhöll de mest 
privilegierade patienterna med lungcancer oftare kurativ syftande behandling och hade även en 
bättre överlevnad, något som var speciellt tydligt bland patienter med lungcancer i tidiga 
stadier. Vi observerade även sociala skillnader i handläggning av män med högrisk 
prostatacancer. Sannolikheten att genomgå skelettscintigrafi, erhålla kurativt syftande 
behandling och opereras var högre bland män med hög socioekonomiskt status, vilka även 
hade en lägre dödlighet i sin prostatacancersjukdom.  
 
Prostatacancerpatienter med hög samtidig annan sjukdomsbörda erhöll i mindre utsträckning 
behandling i kurativt syfte, och hade en högre total dödlighet och av andra orsaker, men inte 
avseende död i prostatacancer. Däremot, givet att prostatacancerpatienterna inte avled av 
andra orsaker, var dödligheten högre i gruppen med hög annan sjukdomsbörda jämfört med 
gruppen utan känd samsjuklighet.  
 
Sammanfattningsvis visar våra resultat på förekomsten av socioekonomiska skillnader i 
handläggning och överlevnad för patienter med lungcancer i Mellansverige och Sydöstra 
England, och bland svenska patienter med högrisk prostatacancer av högrisktyp. Resultaten 
visar även att komorbiditet både påverkar val av behandling och dödlighet bland 
prostatacancerpatienter. Behandlingsmönster och överlevnad bland de mest privilegierade 
cancerpatienterna visar vad som är uppnåbart och bör utgöra en minimistandard för samtliga 
patienter oavsett bakgrund. 
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